Advertisement

Anti-Epileptic Activity

  • Mary Jeanne Kallman
Reference work entry

Abstract

Epilepsy is a disease of high prevalence, being well known since thousands of years as “morbus sacer.” In spite of intensive investigations, the pathophysiology of epilepsy is still poorly understood. Studies with various animal models have provided ample evidence for heterogeneity in the mechanisms of epileptogenesis. New evidence derives from investigations of kindling, which involves the delivery of brief, initially subliminal, electrical, or chemical stimuli to various areas of the brain. After 10–15 days of once-daily stimulation, the duration and intensity of afterdischarges reach a stable maximum, and a characteristic seizure is produced. Subsequent stimulation then regularly elicits seizures.

References and Further Reading

General Considerations

  1. Cotman CW, Iversen LL (1987) Excitatory amino acids in the brain-focus on NMDA receptors. Trends Neurosci 10:263–265Google Scholar
  2. Fabene PF, Sbarbati A (2004) In vivo MRI in different models of experimental epilepsy. Curr Drug Targets 5:629–636PubMedGoogle Scholar
  3. Fisher RS (1989) Animal models of the epilepsies. Brain Res Rev 14:245–278PubMedGoogle Scholar
  4. Gale K (1992) GABA and epilepsy: basic concepts from preclinical research. Epilepsia 33(Suppl 5):S3–S12PubMedGoogle Scholar
  5. Hout J, Raduoco-Thomas S, RaduocoThomas C (1973) Qualitative and quantitative evaluation of experimentally induced seizures. In: Anticonvulsant drugs, vol 1. Pergamon Press, Oxford/New York, pp 123–185Google Scholar
  6. Koella WP (1985) Animal experimental methods in the study of antiepileptic drugs. In: Frey HH, Janz D (eds) Antiepileptic drugs. Handbook of experimental pharmacology, vol 74. Springer, Berlin/Heidelberg, pp 283–339Google Scholar
  7. Löscher W (1997) Animal models of intractable epilepsy. Prog Neurobiol 53:239–258PubMedGoogle Scholar
  8. Löscher W (1998) New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 342:1–13Google Scholar
  9. Löscher W (2002a) Animal models of drug-resistant epilepsy. Novartis Found Symp 243:149–159Google Scholar
  10. Löscher W (2002b) Animal models of epilepsy for the development of antiepileptic and disease-modifying drugs. A comparison of the pharmacology of kindling and poststatus epilepticus models of temporal epilepsy. Epilepsy Res 50:105–123Google Scholar
  11. Löscher W, Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:145–181PubMedGoogle Scholar
  12. MacDonald RL, McLean MJ (1986) Anticonvulsant drugs: mechanisms of action. Adv Neurol 44:713–736PubMedGoogle Scholar
  13. Meldrum BS (1986) Pharmacological approaches to the treatment of epilepsy. In: Meldrum BS, Porter RJ (eds) New anticonvulsant drugs. John Libbey, London/Paris, pp 17–30Google Scholar
  14. Meldrum BS (1989) GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Pharmacol 27:3S–11SGoogle Scholar
  15. Porter RJ, Rogawski MA (1992) New antiepileptic drugs: from serendipity to rational discovery. Epilepsia 33(Suppl 1):S1–S6PubMedGoogle Scholar
  16. Rogawski MA, Porter RJ (1990) Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42:223–286Google Scholar
  17. Rump S, Kowalczyk M (1987) Effects of antiepileptic drugs in electrophysiological tests. Pol J Pharmacol Pharm 39:557–566PubMedGoogle Scholar
  18. Smyth MD, Barbaro NM, Baraban SC (2002) Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia. Epilepsy Res 50:251–264Google Scholar
  19. Swinyard EA (1973) Assay of antiepileptic drug activity in experimental animals: standard tests. In: Anticonvulsant drugs, vol 1. Pergamon Press, Oxford/New York, pp 47–65Google Scholar
  20. Toman JEP, Everett GM (1964) Anticonvulsants. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities: pharmacometrics. Academic, London/New York, pp 287–300Google Scholar
  21. Watkins JC, Olverman HJ (1987) Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci 10:265–272Google Scholar
  22. Woodbury DM (1972) Applications to drug evaluations. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy – a manual for the laboratory worker. Raven, New York, pp 557–583Google Scholar

GABAB Receptor Binding

  1. Fonnum F (1987) Biochemistry, anatomy, and pharmacology of GABA neurons. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 173–182Google Scholar
  2. Lloyd KG, Morselli PL (1987) Psychopharmacology of GABAergic drugs. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York pp 183–195Google Scholar

3H-GABA Uptake in Rat Cerebral Cortex Synaptosomes

  1. Brehm L et al (1979) GABA uptake inhibitors and structurally related “pro-drugs”. In: Krogsgaard-Larsen P et al (eds) GABA-neurotransmitters. Academic, New York, pp 247–261Google Scholar
  2. Fjalland B (1978) Inhibition by neuroleptics of uptake of3H GABA into rat brain synaptosomes. Acta Pharmacol Toxicol 42:73–76Google Scholar
  3. Gray EG, Whittaker VP (1962) The isolation of nerve endings from brain: an electron microscopic study of cell fragments derived by homogenization and centrifugation. J Anat (Lond) 96:79–88Google Scholar
  4. Iversen LL, Bloom FE (1972) Studies of the uptake of3HGABA and3H-glycine in slices and homogenates of rat brain and spinal cord by electron microscopic autoradiography. Brain Res 41:131–143PubMedGoogle Scholar
  5. Korgsgaard-Larsen P (1985) GABA agonist and uptake inhibitors. Research Biochemicals Incorporated – Neurotransmissions 1Google Scholar
  6. Meldrum B et al (1982) GABA-uptake inhibitors as anticonvulsant agents. In: Okada Y, Roberts E (eds) Problems in GABA research from brain to bacteria. Excerpta Medica, Princeton, pp 182–191Google Scholar
  7. Roberts E (1974) γ-Aminobutyric acid and nervous system function – a perspective. Biochem Pharmacol 23:2637–2649PubMedGoogle Scholar
  8. Roskoski R (1978) Net uptake of l-glutamate and GABA by high affinity synaptosomal transport systems. J Neurochem 31:493–498Google Scholar
  9. Ryan L, Roskoski R (1977) Net uptake of γ-Aminobutyric acid by a high affinity synaptosomal transport system. J Pharm Exp Ther 200:285–291Google Scholar
  10. Snodgrass SR (1990) GABA and GABA neurons: Controversies, problems, and prospects. In: Receptor site analysis. NEN, pp 23–33Google Scholar
  11. Tapia R (1975) Blocking of GABA uptake. In: Iversen I, Iversen S, Snyder S (eds) Handbook of psychopharmacology, vol 4. Plenum Press, New York, pp 33–34Google Scholar

GABA Uptake and Release in Rat Hippocampal Slices

  1. Akaike N, Moorhouse AJ (2003) Techniques: applications of the nerve-bouton preparation in neuropharmacolgy. Trends Pharmacol Sci 24:44–47PubMedGoogle Scholar
  2. Akaike N, Muarkami N, Katsurabayashi S, Jin YH, Imazawa T (2002) Focal stimulation of single GABAergic presynaptic boutons on the rat hippocampus neuron. Neurosci Res 42:187–195PubMedGoogle Scholar
  3. Drewe JA, Childs GV, Kunze DL (1988) Synaptic transmission between dissociated adult mammalian neurons and attached synaptic boutons. Science 241:1810–1813PubMedGoogle Scholar
  4. Falch E, Larsson OM, Schousboe A, Krogsgard-Larsen P (1990) GABA-A agonists and GABA uptake inhibitors. Drug Dev Res 21:169–188Google Scholar
  5. Haage D, Karlsson U, Johansson S (1998) Heterogeneous presynaptic Ca2+ channel types triggering GABA release onto medial preoptic neurons from rat. J Physiol (Lond) 507:77–91Google Scholar
  6. Huger FP, Smith CP, Chiang Y, Glamkowski EJ, Ellis DB (1987) Pharmacological evaluation of HP 370, a potential atypical anti-psychotic agent. 2. in vitro profile. Drug Dev Res 11:169–175Google Scholar
  7. Jang IS, Rhee JS, Watanabe T, Akaike N, Akaike N (2001) Histaminergic modulation of GABAergic transmission in rat ventromedial hypothalamic neurons. J Physiol (Lond) 534:791–803Google Scholar
  8. Kishimoto K, Koyama S, Akaike N (2001) Synergistic μ-opioid and 5-HT1A presynaptic inhibition of GABA release in rat periaqueductal gray neurons. Neuropharmacology 41:529–538PubMedGoogle Scholar
  9. Koyama S, Kubo C, Rhee JS, Akaike N (1999) Presynaptic serotonergic inhibition of GABAergic synaptic transmission in mechanically dissociated rat basolateral amygdala neurons. J Physiol (Lond) 518:525–538Google Scholar
  10. Lajtha A, Sershen H (1975) Inhibition of amino acid uptake by the absence of Na+ in slices of brain. J Neurochem 24:667–672PubMedGoogle Scholar
  11. Lüddens H, Korpi ER (1995) Biological function of GABAA/ benzodiazepine receptor heterogeneity. J Psychiat Res 29:77–94PubMedGoogle Scholar
  12. Möhler H (1992) GABAergic synaptic transmission. Arzneim Forsch/Drug Res 42:211–214Google Scholar
  13. Nilsson M, Hansson E, Rönnbäck L (1990) Transport of valproate and its effects on GABA uptake in astroglial primary culture. Neurochem Res 15:763–767PubMedGoogle Scholar
  14. Nilsson M, Hansson E, Rönnbäck L (1992) Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochem Res 17:327–332PubMedGoogle Scholar
  15. Rhee JS, Ishibashi H, Akaike N (1999) Calcium channels in the GABAergic presynaptic nerve terminals projecting to Meynert neurons of the rat. J Neurochem 72:800–806PubMedGoogle Scholar
  16. Roskoski R (1978) Net uptake of l-glutamate and GABA by high affinity synaptosomal transport systems. J Neurochem 31:493–498Google Scholar
  17. Suzdak PD, Jansen JA (1995) A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36:612–626PubMedGoogle Scholar
  18. Taylor CP (1990) GABA receptors and GABAergic synapses as targets for drug development. Drug Dev Res 21:151–160Google Scholar
  19. Taylor CP, Vartanian MG, Schwarz RD, Rock DM, Callahan MJ, Davis MD (1990) Pharmacology of CI-966: a potent GABA uptake inhibitor, in vitro and in experimental animals. Drug Dev Res 21:195–215Google Scholar
  20. Vorobjev VS (1991) Vibrodissociation of sliced mammalian nervous tissue. J Neurosci Methods 38:145–150PubMedGoogle Scholar
  21. Walton NY, Gunnawan S, Treiman DM (1994) Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine. Epilepsy Res 19:237–244Google Scholar

Glutamate Receptors: [3H]CPP Binding

  1. Becker J, Li Z, Noe CR (1998) Molecular and pharmacological characterization of recombinant rat/mice N-methyl-d-aspartate receptor subtypes in the yeast Saccharomyces cerevisiae. Eur J Biochem 256:427–435PubMedGoogle Scholar
  2. Bettler B, Mulle C (1995) Review: neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacol 34:123–139Google Scholar
  3. Bräuner-Osboren H, Egebjerg J, Nielsen NØ, Madsen U, Krogsgaard-Larsen P (2000) Ligands for glutamate receptors: design and therapeutic properties. J Med Chem 43:2609–2645Google Scholar
  4. Carlsson M, Carlsson A (1990) Interactions between glutaminergic and monoaminergic systems within the basal ganglia – implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13:272–276PubMedGoogle Scholar
  5. Carter C, Rivy JP, Scatton B (1989) Ifenprodil and SL 82.0715 are antagonists at the polyamine site of the N-methyl-d-aspartate (NMDA) receptor. Eur J Pharmacol 164:611–612PubMedGoogle Scholar
  6. Chimirri A, Gitto R, Zappala M (1999) AMPA receptor antagonists. Expert Opin Ther Pat 9:557–570Google Scholar
  7. Chittajallu R, Braithwaite SP, Clarke VRJ, Henley JM (1999) Kainate receptors: subunits, synaptic localization and function. Trends Pharmacol Sci 20:26–35PubMedGoogle Scholar
  8. Clarke VRJ, Ballyk BA, Hoo KH, Mandelzys A, Pellizari A, Bath CP, Thomas J, Sharpe EF, Davies CH, Ornstein PL, Schoepp DD, Kamboj RK, Collingridge GL, Lodges D, Bleakman D (1997) A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 389:599–603PubMedGoogle Scholar
  9. Collingridge GL, Lester RAJ (1989) Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 40:143–210Google Scholar
  10. Cotman CW, Iversen LL (1987) Excitatory amino acids in the brain-focus on NMDA receptors. Trends Neurosci 10:263–265Google Scholar
  11. Cunningham MD, Ferkany JW, Enna SH (1994) Excitatory amino acid receptors: a gallery of new targets for pharmacological intervention. Life Sci 54:135–148PubMedGoogle Scholar
  12. Danysz W, Parsons CG (1998) Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597–664PubMedGoogle Scholar
  13. Davies J, Evans RH, Herrling PL, Jones AW, Olverman HJ, Pook P, Watkins JC (1986) CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for [3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res 382:169–173PubMedGoogle Scholar
  14. Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7–61PubMedGoogle Scholar
  15. Dunn RW, Corbett R, Martin LL, Payack JF, Laws-Ricker L, Wilmot CA, Rush DK, Cornfeldt ML, Fielding S (1990) Preclinical anxiolytic profiles of 7189 and 8319, novel non-competitive NMDA antagonists. Current and future trends in anticonvulsant, anxiety, and stroke therapy. Wiley-Liss, pp 495–512Google Scholar
  16. Ferkany J, Coyle JT (1986) Heterogeneity of sodium-dependent excitatory amino acid uptake mechanisms in rat brain. J Neurosci Res 16:491–503PubMedGoogle Scholar
  17. Fleck AW, Bahring R, Patneau DK, Mayer ML (1996) AMPA receptor heterogeneity in rat hippocampal neurons revealed by differential sensitivity to cyclothiazide. J Neurophysiol 75:2322–2333PubMedGoogle Scholar
  18. Fletcher EJ, Lodge D (1995) New developments in the molecular pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Pharmacol Ther 70:65–89Google Scholar
  19. Foster AC, Fagg GE (1984) Acidic amino acid binding sites in mammalian neuronal membranes: their characteristics and relationship to synaptic receptors. Brain Res Rev 7:103–164Google Scholar
  20. Foster AC, Fagg GE (1987) Comparison of l-[3H]glutamate, d-[3H]aspartate, DL-[3H]AP5 and [3H]NMDA as ligands for NMDA receptors in crude postsynaptic densities from rat brain. Eur J Pharmacol 133:291–300PubMedGoogle Scholar
  21. Gallo V, Ghiani CA (2000) Glutamate receptors in glia: new cells, new inputs and new functions. Trends Pharmacol Sci 21:252–258PubMedGoogle Scholar
  22. Harris EW, Ganong AH, Monaghan DT, Watkins JC, Cotman CW (1986) Action of 3-((±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP): a new and highly potent antagonist of N-methyl-d-aspartate receptors in the hippocampus. Brain Res 382:174–177PubMedGoogle Scholar
  23. Hatt H (1999) Modification of glutamate receptor channels: molecular mechanisms and functional consequences. Naturwissenschaften 86:177–186PubMedGoogle Scholar
  24. Herrling PL (1994) Clinical implications of NMDA receptors. In: Collingridge GL, Watkins JC (eds) The NMDA receptor, 2nd edn. Oxford University Press, Oxford, pp 376–394Google Scholar
  25. Hollmann M, Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31–108Google Scholar
  26. Honoré T, Lauridsen J, Krogsgaard-Larsen P (1982) The binding of [3H]AMPA, a structural analogue of glutamic acid to rat brain membranes. J Neurochem 38:173–178PubMedGoogle Scholar
  27. Honoré T, Davies SN, Drejer J, Fletchner EJ, Jacobsen P, Lodge D, Nielsen FE (1988) Quinoxalidinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241:701–703PubMedGoogle Scholar
  28. Hu RQ, Koh S, Togerson T, Cole AJ (1998) Neuronal stress and injury in C57/BL mice after systemic kainate administration. Brain Res 810:229–240Google Scholar
  29. Huettner JE (2003) Kainate receptors and synaptic transmission. Prog Neurobiol 70:387–407PubMedGoogle Scholar
  30. Iversen LL, Kemp JA (1994) Non-competitive NMDA antagonists as drugs. In: Collingridge GL, Watkins JC (eds) The NMDA receptor, 2nd edn. Oxford University Press, Oxford, pp 469–486Google Scholar
  31. Jones SM, Snell LD, Johnson KM (1989) Characterization of the binding of radioligands to the N-methyl-d-aspartate, phenylcyclidine and glycine receptors in buffy coat membranes. J Pharmacol Methods 21:161–168PubMedGoogle Scholar
  32. Kemp JA, McKernan RM (2002) NMDA receptor pathways as drug targets. Nat Neurosci Suppl 5:1039–1042Google Scholar
  33. Kemp JA, Foster AC, Wong EHF (1987) Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci 10:294–298Google Scholar
  34. Kodama M, Yamada M, Sato K, Kitamura Y, Koyama F, Sato T, Morimoto K, Kuroda S (1999) Effects of YM90K, a selective AMP receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in rats. Eur J Pharmacol 374:11–19PubMedGoogle Scholar
  35. Kohara A, Okada M, Tsutsumi R, Ohno K, Takahashi M, Shimizu-Sasamata M, Shishikura JI, Inami H, Sakamoto S, Yamaguchi T (1998) In vitro characterization of YM872, a selective, potent and highly water-soluble α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate receptor antagonist. J Pharm Pharmacol 50:795–801PubMedGoogle Scholar
  36. Lees GJ (2000) Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drug 59:33–78Google Scholar
  37. Lehmann J, Schneider J, McPherson S, Murphy DE, Bernard P, Tsai C, Bennett DA, Pastor G, Steel DJ, Boehm C, Cheney DL, Liebman JM, Williams M, Wood PL (1987) CPP, a selective N-methyl-d-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo. J Pharmacol Exp Ther 240:737–746PubMedGoogle Scholar
  38. Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy DE, Steel DJ, Williams M, Cheney DL, Wood PL (1988) CGS 19755, a selective and competitive N-methyl-d-aspartate type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther 246:65–75PubMedGoogle Scholar
  39. Loftis JM, Janowsky A (2003) The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 97:55–85PubMedGoogle Scholar
  40. London ED, Coyle JT (1979) Specific binding of [3H]kainic acid to receptor sites in rat brain. Mol Pharmacol 15:492–505PubMedGoogle Scholar
  41. Löscher W (1998) Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol 54:721–741Google Scholar
  42. Lynch G (2004) AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 4:4–11Google Scholar
  43. Mayer ML, Armstrong N (2004) Structure and function of glutamate receptor ion channels. Annu Rev Physiol 66:161–181PubMedGoogle Scholar
  44. Mayer ML, Westbrook GL (1987) The physiology of excitatory amino acids in the vertebrate central nervous system. Prog Neurobiol 28:197–276PubMedGoogle Scholar
  45. Mayer ML, Benveniste M, Patneau DK (1994) NMDA receptor agonists and competitive antagonists. In: Collingridge GL, Watkins JC (eds) The NMDA receptor, 2nd edn. Oxford University Press, Oxford, pp 132–146Google Scholar
  46. Meldrum BS (1998) The glutamate synapse as a therapeutic target: perspectives for the future. Prog Brain Res 116:441–458PubMedGoogle Scholar
  47. Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 130(4S Suppl):1007S–1015SPubMedGoogle Scholar
  48. Meldrum BS, Chapman AG (1994) Competitive NMDA antagonists as drugs. In: Collingridge GL, Watkins JC (eds) The NMDA receptor, 2nd edn. Oxford University Press, Oxford, pp 457–468Google Scholar
  49. Monaghan DT, Buller AL (1994) Anatomical, pharmacological, and molecular diversity of native NMDA receptor subtypes. In: Collingridge GL, Watkins JC (eds) The NMDA receptor, 2nd edn. Oxford University Press, Oxford, pp 158–176Google Scholar
  50. Monaghan DT, Cotman CW (1982) The distribution of [3H]kainic acid binding sites in rat CNS as determined by autoradiography. Brain Res 252:91–100PubMedGoogle Scholar
  51. Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29:365–402PubMedGoogle Scholar
  52. Mukhin A, Kovaleva ES, London ED (1997) Two affinity states of N-methyl-d-aspartate recognition sites: modulation by cations. J Pharmacol Exp Ther 282:945–954PubMedGoogle Scholar
  53. Murphy DE, Schneider J, Boehm C, Lehmann J, Williams M (1987a) Binding of [3H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to rat brain membranes: a selective, high-affinity ligand for N-methyl-d-aspartate receptors. J Pharmacol Exp Ther 240:778–784PubMedGoogle Scholar
  54. Murphy DE, Snowhill EW, Williams M (1987b) Characterization of quisqualate recognition sites in rat brain tissue using DL-[3H]α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay. Neurochem Res 12:775–782PubMedGoogle Scholar
  55. Murphy DE, Hutchinson AJ, Hurt SD, Williams M, Sills MA (1988) Characterization of the binding of [3H]-CGS 19755, a novel N-methyl-d-aspartate antagonist with nanomolar affinity in rat brain. Br J Pharmacol 95:932–938PubMedCentralPubMedGoogle Scholar
  56. Mutel V, Trube G, Klingelschmidt A, Messer J, Bleuel Z, Humbel U, Clifford MM, Ellis GJ, Richards JG (1998) Binding characteristics of a potent AMPA receptor antagonist [3H]Ro 48–8587 in rat brain. J Neurochem 71:418–426PubMedGoogle Scholar
  57. Nakanishi S (1992) Molecular diversity of glutamate receptors and implication for brain function. Science 258:593–603Google Scholar
  58. Nielsen EO, Varming T, Mathiesen C, Jensen LH, Moller A, Gouliaev AH, Watjen F, Drejer J (1999) SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. J Pharmacol Exp Ther 289:1492–1501PubMedGoogle Scholar
  59. Olney JW (1990) Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol 30:47–71PubMedGoogle Scholar
  60. Olsen RW, Szamraj O, Houser CR (1987) [3H]AMPA binding to glutamate receptor subpopulations in rat brain. Brain Res 402:243–254PubMedGoogle Scholar
  61. Olverman JH, Monaghan DT, Cotman CW, Watkins JC (1986) [3H]CPP, a new competitive ligand for NMDA receptors. Eur J Pharmacol 131:161–162PubMedGoogle Scholar
  62. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development. Drug News Perspect 11:523–569PubMedGoogle Scholar
  63. Piotrovsky LB, Garyaev AP, Poznyakova LN (1991) Dipeptide analogues of N-acetylaspartylglutamate inhibit convulsive effects of excitatory amino acids in mice. Neurosci Lett 125:227–230PubMedGoogle Scholar
  64. Rogawski MA, Porter RJ (1990) Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with considerations of promising developmental stage compounds. Pharmacol Rev 42:223–286Google Scholar
  65. Tauboll E, Gjerstad L (1998) Effects of antiepileptic drugs on the activation of glutamate receptors. Prog Brain Res 116:385–393PubMedGoogle Scholar
  66. Thomsen C (1997) The L-AP4 receptor. Gen Pharmacol 29:151–158PubMedGoogle Scholar
  67. Toms NJ, Reid ME, Phillips W, Kemp MC, Roberts PJ (1997) A novel kainate receptor ligand [3H]-(2S,4R)-4-methylglutamate. Pharmacological characterization in rabbit brain membranes. Neuropharmacology 36:1483–1488PubMedGoogle Scholar
  68. Wahl P, Frandsen A, Madsen U, Schousboe A, Krogsgaard-Larsen P (1998) Pharmacology and toxicology of ATOA, an AMPA receptor antagonist and a partial agonist at GluR5 receptors. Neuropharmacology 37:1205–1210PubMedGoogle Scholar
  69. Watkins JC (1994) The NMDA receptor concept: origins and development. In: Collingridge GL, Watkins JC (eds) The NMDA receptor, 2nd edn. Oxford University Press, Oxford, pp 1–30Google Scholar
  70. Watkins JC, Olverman HJ (1987) Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci 10:265–272Google Scholar
  71. Willis CL, Wacker DA, Bartlett RD, Bleakman D, Lodge D, Chamberlin AR, Bridges RJ (1997) Irreversible inhibition of high affinity [3H]kainate binding by a photoactivatable analogue: (2′S,3′S,4′R)-2′-carboxy-4′-(2-diazo-1-oxo-3,3,3-trifluoropropyl)-3′-pyrrolidinyl acetate. J Neurochem 68:1503–1510PubMedGoogle Scholar
  72. Worms P, Willigens MT, Lloyd KG (1981) The behavioral effects of systemically administered kainic acid: a pharmacological analysis. Life Sci 29:2215–2225PubMedGoogle Scholar
  73. Young AB, Fagg GE (1990) Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. Trends Pharmacol Sci 11:126–133PubMedGoogle Scholar
  74. Zeman S, Lodge D (1992) Pharmacological characterization of non-NMDA subtypes of glutamate receptor in the neonatal rat hemidissected spinal cord in vitro. Br J Pharmacol 106:367–372Google Scholar
  75. Zhou L-L, Gu ZQ, Costa AM, Yamada KA, Mansson PE, Giordano T, Skolnick P, Jones KA (1997) (2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high affinity ligand for kainate receptors. J Pharmacol Exp Ther 280:422–427PubMedGoogle Scholar

NMDA Receptor Complex: [3H]TCP Binding

  1. Abe T, Sugihara H, Nawa H, Shigemoto R, Mizuno N, Nakanishi S (1992) Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem 267:13361–13368PubMedGoogle Scholar
  2. Bashir ZI, Bortolotto ZA, Davies CH, Berretta M, Irving AJ, Seal AJ, Henley AM, Jane DE, Watkins JC, Collingridge GL (1993) Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature 363:347–350PubMedGoogle Scholar
  3. Bednar B, Cunningham ME, Kiss L, Cheng G, McCauley JA, Liverton NJ, Koblan KS (2004) Kinetic characterization of novel NR2B antagonists using fluorescence detection of calcium flux. J Neurosci Methods 137:247–255PubMedGoogle Scholar
  4. Chenard BL, Menniti FS (1999) Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Res 5:381–404Google Scholar
  5. Cotman CW, Iversen LL (1987) Excitatory amino acids in the brain-focus on NMDA receptors. Trends Neurosci 10:263–265Google Scholar
  6. Dannhardt G, von Gruchalla M, Elben U (1994) Tools for NMDA-receptor elucidation: synthesis of spacer-coupled MK-801 derivatives. Pharm Pharmacol Lett 4:12–15Google Scholar
  7. Dunn RW, Corbett R, Martin LL, Payack JF, Laws-Ricker L, Wilmot CA, Rush DK, Cornfeldt ML, Fielding S (1990) Preclinical anxiolytic profiles of 7189 and 8319, novel non-competitive NMDA antagonists. Current and future trends in anticonvulsant, anxiety, and stroke therapy. Wiley-Liss, pp 495–512Google Scholar
  8. Ebert B, Madsen U, Lund TM, Lenz SM, Krogsgaard-Larsen P (1994) Molecular pharmacology of the AMPA agonist, (S)-2-amino-3-(3-hydroxy-5-phenyl-4-isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, (R)-APPA. Neurochem Int 24:507–515PubMedGoogle Scholar
  9. Fischer G, Mutel V, Trube G, Malherbe P, Kew JNC, Mohacsi E, Heitz MP, Kemp JA (1997) Ro 25–6981, a highly potent and selective blocker of N-methyl-d-aspartate receptors containing the NRB2 subunit. J Pharmacol Exp Ther 283:1285–1292PubMedGoogle Scholar
  10. Goldman ME, Jacobson AE, Rice KC, Paul SM (1985) Differentiation of [3H]phencyclidine and (+)-[3H]SKΒ-10,047 binding sites in rat cerebral cortex. FEBS Lett 190:333–336PubMedGoogle Scholar
  11. Grimwood S, ILe Bourdellès B, Atack JR, Barton C, Cockettt W, Cook SM, Gilbert E, Hutson PH, McKernan RM, Myers J, Ragan CI, Wingrove PB, Whiting PJ (1996) Generation and characterization of stable cell lines expressing recombinant human N-methyl-d-aspartate receptor subtypes. J Neurochem 66:2239–2247PubMedGoogle Scholar
  12. Hansen JJ, Krogsgaard-Larsen P (1990) Structural, conformational, and stereochemical requirements of central excitatory amino acid receptors. Med Res Rev 10:55–94PubMedGoogle Scholar
  13. Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H, Yokoi M, Akazawa C, Shigemoto R, Mizuno N, Masu M, Nakanishi S (1993) Molecular characterization of the family of N-methyl-d-aspartate receptor subunits. J Biol Chem 268:2836–2843PubMedGoogle Scholar
  14. Iversen LL (1994) MK-801 (Dizocilpine maleate) – NMDA receptor antagonist. Neurotransmission 10(1):1–4Google Scholar
  15. Javitt DC, Zukin SR (1989) Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-d-aspartate receptor channels. Mol Pharmacol 35:387–393PubMedGoogle Scholar
  16. Johnson KM, Jones SM (1990) Neuropharmacol of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30:707–750PubMedGoogle Scholar
  17. Keinänen K, Wisden W, Sommer B, Werner P, Herb A, Verdoorn TA, Sakmann B, Seeburg PH (1990) A family of AMPA-selective glutamate receptors. Science 249:556–560PubMedGoogle Scholar
  18. Kemp JA, Foster AC, Wong EHF (1987) Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci 10:294–298Google Scholar
  19. Kew JNC, Trube G, Kemp JA (1998) State-dependent NMDA receptor antagonism by Ro 8–4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br J Pharmacol 123:463–472PubMedCentralPubMedGoogle Scholar
  20. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushyia E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, Mishina M (1992) Molecular diversity of the NMDA receptor channel. Nature 358:36–41PubMedGoogle Scholar
  21. Loo P, Braunwalder A, Lehmann J, Williams M (1986) Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists. Eur J Pharmacol 123:467–468PubMedGoogle Scholar
  22. Loo PS, Braunwalder AF, Lehmann J, Williams M, Sills MA (1987) Interaction of l-glutamate and magnesium with phencyclidine recognition sites in rats brain: evidence for multiple affinity states of the phencyclidine/N-methyl-d-aspartate receptor complex. Mol Pharmacol 32:820–830PubMedGoogle Scholar
  23. Maragos WF, Chu DCM, Greenamyre T, Penney JB, Young AB (1986) High correlation between the localization of [3H]TCP binding and NMDA receptors. Eur J Pharmacol 123:173–174PubMedGoogle Scholar
  24. Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S (1991) Sequence and expression of a metabotropic glutamate receptor. Nature 349:760–765PubMedGoogle Scholar
  25. Meguro H, Mori H, Araki K, Kushiya E, Katsuwada T, Yamazaki M, Kumanishi T, Arakawa M, Sakimura K, Mishina M (1992) Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 357:70–74PubMedGoogle Scholar
  26. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256:1217–1221PubMedGoogle Scholar
  27. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354:31–37PubMedGoogle Scholar
  28. Nakajima Y, Iwakabe H, Akazawa C, Nawa H, Shigemoto R, Mizuno N, Nakanishi N (1993) Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for l-2-amino-4-phosphonobutyrate. J Biol Chem 268:11868–11873PubMedGoogle Scholar
  29. Nowak G, Remond A, McNamara M, Paul IA (1995) Swim stress increases the potency of glycine at the N-methyl-d-aspartate receptor complex. J Neurochem 64:925–927PubMedGoogle Scholar
  30. Reyes M, Reyes A, Opitz T, Kapin MA, Stanton PK (1998) Eliprodil, a non-competitive, NR2B-selective NMDA antagonist, protects pyramidal neurons in hippocampal slides from hypoxic/ischemic damage. Brain Res 782:212–218PubMedGoogle Scholar
  31. Reynolds IJ, Miller RJ (1988) Multiple sites for the regulation of the N-methyl-d-aspartate receptor. Mol Pharmacol 33:581–584PubMedGoogle Scholar
  32. Rogawski MA, Porter RJ (1990) Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with considerations of promising developmental stage compounds. Pharmacol Rev 42:223–286Google Scholar
  33. Sacaan AI, Johnson KM (1989) Spermine enhances binding to the glycine site associated with the N-methyl-d-aspartate receptor complex. Mol Pharmacol 36:836–839Google Scholar
  34. Schoepp D, Bockaert J, Sladeczek F (1990) Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors. Trends Pharmacol Sci 11:508–515PubMedGoogle Scholar
  35. Sills MA, Fagg G, Pozza M, Angst C, Brundish DE, Hurt SD, Wilusz EJ, Williams M (1991) [3H]CGP 39653: a new N-methyl-d-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur J Pharmacol 192:19–24PubMedGoogle Scholar
  36. Simon RP, Swan JH, Griffiths T, Meldrum BS (1984) Blockade of N-methyl-d-aspartate receptors may protect against ischemic damage in the brain. Science 226:850–852PubMedGoogle Scholar
  37. Snell LD, Morter RS, Johnson KM (1987) Glycine potentiates N-methyl-d-aspartate-induced [3H]TCP binding to rat cortical membranes. Neurosci Lett 83:313–320Google Scholar
  38. Snell LD, Morter RS, Johnson KD (1988) Structural requirements for activation of the glycine receptor that modulates the N-methyl-d-aspartate operated ion channel. Eur J Pharmacol 156:105–110Google Scholar
  39. Sugihara H, Moriyoshi K, Ishii T, Masu M, Nakanishi S (1992) Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochem Biophys Res Commun 185:826–832PubMedGoogle Scholar
  40. Tanabe Y, Nomura A, Masu M, Shigemoto R, Mizuno N, Nakanishi S (1993) Signal transduction, pharmacological properties, and expression patterns of two metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci 13:1372–1378Google Scholar
  41. Thedinga KH, Benedict MS, Fagg GE (1989) The N-methyl-d-aspartate (NMDA) receptor complex: a stoichiometric analysis of radioligand binding domains. Neurosci Lett 104:217–222PubMedGoogle Scholar
  42. Thomson AM (1989) Glycine modulation of the NMDA receptor/channel complex. Trends Neurosci 12:349–353Google Scholar
  43. Vignon J, Chicheportiche R, Chicheportiche M, Kamenka JM, Geneste P, Lazdunski M (1983) [3H]TPC: a new tool with high affinity to the PCP receptor in rat brain. Brain Res 280:194–197PubMedGoogle Scholar
  44. Watkins JC, Olverman HJ (1987) Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci 10:265–272Google Scholar
  45. Watkins JC, Krogsgaard-Larsen P, Honoré T (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 11:25–33PubMedGoogle Scholar
  46. Williams K, Romano C, Molinoff PB (1989) Effects of polyamines on the binding of [3H]MK-801 to the N-methyl-d-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site. Mol Pharmacol 36:575–581PubMedGoogle Scholar
  47. Wong EHF, Kemp JA (1991) Sites for antagonism on the N-methyl-d-aspartate receptor channel complex. Annu Rev Pharmacol Toxicol 31:401–425PubMedGoogle Scholar
  48. Wong EHF, Knight AR, Woodruff GN (1988) [3H]MK-801 labels a site on the N-methyl-d-aspartate receptor channel complex in rat brain membranes. J Neurochem 50:274–281PubMedGoogle Scholar
  49. Yoneda Y, Ogita K (1991) Neurochemical aspects of the N-methyl-d-aspartate receptor complex. Neurosci Res 10:1–33PubMedGoogle Scholar

Metabotropic Glutamate Receptors

  1. Acher FC, Tellier FJ, Azerad R, Brabet IN, Fagni L, Pin JPR (1997) Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem 40:3119–3129PubMedGoogle Scholar
  2. Alexander S, Peters J, Mathie A, MacKenzie G, Smith A (2001) TiPS nomenclature supplementGoogle Scholar
  3. Annoura H, Fukunaga A, Uesugi M, Tatsuoka T, Horikawa Y (1996) A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)-cyclopropa[b]chromenla-carboxylates. Bioorg Med Chem Lett 6:763–766Google Scholar
  4. Attwell PJE, Singh-Kent N, Jane D, Croucher MJ, Bradford HF (1998) Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2′ R,3′R)-2-(2′ 3′ dicarboxycyclopropyl)-glycine (DCG-IV). Brain Res 805:138–143PubMedGoogle Scholar
  5. Bedingfield JS, Jane DE, Kemp MC, Toms NJ, Roberts PJ (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur J Pharmacol 309:71–78PubMedGoogle Scholar
  6. Berridge MJ, Downes CP, Hanley MR (1982) Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 206:587–595PubMedCentralPubMedGoogle Scholar
  7. Brauner-Osborne H, Nielsen B, Krogsgaard-Larsen P (1998) Molecular pharmacology of homologues of ibotenic acid at cloned metabotropic glutamic acid receptors. Eur J Pharmacol 350:311–316PubMedGoogle Scholar
  8. Bruno V, Battaglia G, Copani A, Casabona G, Storto M, di Giorgi-Gerevini V, Ngomba R, Nicoletti F (1998) Metabotropic glutamate receptors and neurodegeneration. Prog Brain Res 116:209–221PubMedGoogle Scholar
  9. Cartmell J, Adam G, Chaboz S, Henningsen R, Kemp JA, Klingelschmidt A, Metzler V, Monsma F, Schaffhauser H, Wichmann J, Mutel V (1998) Characterization of [3H](2S,2′R,3′R)-2-(2′, 3′-dicarboxycyclopropyl)glycine ([3H]DCG IV) binding to metabotropic mGlu2 receptor transfected cell membranes. Br J Pharmacol 123:497–504PubMedCentralPubMedGoogle Scholar
  10. Christoffersen GRJ, Christensen LH, Hammer P, Vang M (1999) The class I metabotropic glutamate receptor antagonist, AIDA, improves short-term and impairs long-term memory in a spatial task for rats. Neuropharmacology 38:817–823PubMedGoogle Scholar
  11. Conn PJ (2003) Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci 1003:12–21PubMedGoogle Scholar
  12. Conn PJ, Pin JP (1997) Pharmacology and function of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237PubMedGoogle Scholar
  13. DeBlasi A, Conn PJ, Pin JP, Nicolette F (2001) Molecular determinants of metabotropic glutamate signaling. Trends Pharmacol Sci 22:114–120Google Scholar
  14. Doherty AJ, Palmer MJ, Henley JM, Collingridge GL, Jane DE (1997) (R, S)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36:265–267PubMedGoogle Scholar
  15. Eriksen L, Thomsen C (1995) [3H]-l-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a. Br J Pharmacol 116:3279–3287PubMedCentralPubMedGoogle Scholar
  16. Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ (1999) (R, S)-4-Phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 289:1678–1687PubMedGoogle Scholar
  17. Gssparini F, Kuhn R, Pin JP (2002) Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol 2:43–49Google Scholar
  18. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent and highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651–660PubMedGoogle Scholar
  19. Hollmann M, Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31–108Google Scholar
  20. Ishida M, Akagi H, Shimamoto K, Ohfune Y, Shinozaki H (1990) A potent metabotropic glutamate receptor agonist: electrophysiological actions of a conformationally restricted glutamate analogue in the rat spinal cord and Xenopus oocytes. Brain Res 537:311–314Google Scholar
  21. Ishida M, Saitoh T, Nakamura Y, Kataoka K, Shinozaki H (1994) A novel metabotropic glutamate receptor agonist: (2S,1′ S,2′ R,3′R)-2-(carboxy-3-methoxymethylcyclopropyl)glycine (cis-MCG-I). Eur J Pharmacol Mol Pharmacol Sect 268:267–270Google Scholar
  22. Jane D, Doherty A (2000) Muddling through the mGlu maze? Tocris Rev 13Google Scholar
  23. Jane DE, Jones PLSJ, Pook PCK, Tse HW, Watkins JC (1994) Actions of two new antagonists showing selectivity for different subtypes of metabotropic glutamate receptor in the neonatal spinal cord. Br J Pharmacol 112:809–816Google Scholar
  24. Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD (1998) LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37:1–12PubMedGoogle Scholar
  25. Knöpfel T, Kuhn R, Allgeier H (1995) Metabotropic glutamate receptors: novel targets for drug development. J Med Chem 38:1417–1425PubMedGoogle Scholar
  26. Knöpfel T, Madge T, Nicoletti F (1996) Metabotropic glutamate receptors. Expert Opin Ther Pat 6:1061–1067Google Scholar
  27. Konieczny J, Ossowska K, Wolfarth S, Pilc A (1998) LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn-Schmiedeberg’s Arch Pharmacol 358:500–502Google Scholar
  28. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL Jr, Wright PA, Johnson PG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, Tizzano JP, Schoepp DD (1999) Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]-hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42:1027–1040PubMedGoogle Scholar
  29. Nakanishi S, Masu M (1994) Molecular diversity and function of glutamate receptors. Annu Rev Biophys Biomol Struct 23:319–348PubMedGoogle Scholar
  30. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T (1996) Metabotropic glutamate receptors: a new target for the treatment of neurodegenerative disorders? Trends Neurosci 19:267–271PubMedGoogle Scholar
  31. Okamoto N, Hori S, Akazawa C, Hayashi Y, Shigemoto R, Mizuno N, Nakanishi S (1994) Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J Biol Chem 269:1231–1236PubMedGoogle Scholar
  32. Ornstein PL, Arnold MB, Bleisch TJ, Wright RA, Wheeler WJ, Schoepp DD (1998) [3H]LY341495, a highly potent, selective and novel radioligand for labeling group II metabotropic glutamate receptors. Bioorg Med Chem Lett 8:1919–1922PubMedGoogle Scholar
  33. Pin JP, Acher F (2002) The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord 1:297–317PubMedGoogle Scholar
  34. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1–26PubMedGoogle Scholar
  35. Porter RHP, Briggs RSJ, Roberts PJ (1992) l-Aspartate-β-hydroxamate exhibits mixed agonist/antagonist activity at the glutamate metabotropic receptor in rat neonatal cerebrocortical slices. Neurosci Lett 144:87–89PubMedGoogle Scholar
  36. Riedel G, Reymann KG (1996) Metabotropic glutamate receptors in hippocampal long-term potentiation and learning and memory. Acta Physiol Scand 157:1–19PubMedGoogle Scholar
  37. Schaffhauser H, Richards JG, Cartmell J, Chaboz S, Kemp JA, Klingelschmidt A, Messer J, Stadler H, Woltering T, Mutel V (1998) In vitro binding characteristics of a new selective group II metabotropic glutamate receptor radioligand, [3H]LY354740, in rat brain. Mol Pharmacol 53:228–233PubMedGoogle Scholar
  38. Schoepp DD, Conn PJ (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 14:13–20PubMedGoogle Scholar
  39. Schoepp DD, Jane DE, Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431–1476PubMedGoogle Scholar
  40. Skerry TM, Genever PG (2001) Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 22:174–181PubMedGoogle Scholar
  41. Tanabe Y, Masu M, Ishii T, Shigemoto R, Nakanishi S (1992) A family of metabotropic glutamate receptors. Neuron 8:169–179PubMedGoogle Scholar
  42. Tanabe Y, Nomura A, Masu M, Shigemoto R, Mizuno N, Nakanishi S (1993) Signal transduction, pharmacological properties, and expression pattern of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci 13:1372–1378Google Scholar
  43. Thomsen C, Dalby NO (1998) Roles of metabotropic glutamate receptor subtypes in modulation of pentylenetetrazole-induced seizure activity in mice. Neuropharmacology 37:1465–1473PubMedGoogle Scholar
  44. Thomsen C, Mulvihill ER, Haldeman B, Pickering DS, Hampson DR, Suzdak PD (1993) A pharmacological characterization of the mGluR1α subtype of the metabotropic glutamate receptor expressed in a cloned baby hamster kidney cell line. Brain Res 619:22PubMedGoogle Scholar
  45. Thomsen C, Boel E, Suzdak PD (1994) Action of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family. Eur J Pharmacol 267:77–84PubMedGoogle Scholar
  46. Thomsen C, Bruno V, Nicoletti F, Marinozzi M, Pelliciari R (1996) (2S,1′S,2′S,3′R)-2-(2′-carboxy-3′-phenylcyclopropyl)glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors. Mol Pharmacol 50:6–9PubMedGoogle Scholar
  47. Varney MA, Suto CM (2000) Discovery of subtype-selective metabotropic glutamate receptor ligands using functional HTS assays. Drug Discov Today HTS Suppl 1:20–26Google Scholar
  48. Watkins J, Collingridge G (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. Trends Pharmacol Sci 15:333–342PubMedGoogle Scholar

Excitatory Amino Acid Transporters

  1. Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG (1994) Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 14:5559–5569PubMedGoogle Scholar
  2. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48–58Google Scholar
  3. Robinson MB, Sinor JD, Dowd LA, Kerwin JF Jr (1993) Subtypes of sodium-dependent high-affinity l-[3H]glutamate transport activity. Pharmacologic specificity and regulation by sodium and potassium. J Neurochem 60:167–179PubMedGoogle Scholar
  4. Seal RP, Amara SG (1999) Excitatory amino acid transporters: a family in flux. Annu Rev Pharmacol Toxicol 39:431–456PubMedGoogle Scholar
  5. Vandenberg RJ (1998) Molecular pharmacology and physiology of glutamate transporters in the central nervous system. Clin Exp Pharmacol Physiol 25:393–400PubMedGoogle Scholar
  6. Vandenberg RJ, Arriza JL, Amara SG, Kavanaugh MP (1995) Constitutive ion fluxes and substrate binding domains of human glutamate transporters. J Biol Chem 270:17668–17671PubMedGoogle Scholar
  7. Vandenberg RJ, Mitrovic AD, Chebib M, Balcar VJ, Johnston GAR (1997) Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol Pharmacol 51:809–815PubMedGoogle Scholar
  8. Woodhull AM (1973) Ion blockage of sodium channels in nerve. J Gen Physiol 61:667–708Google Scholar

[35S]TBPS Binding in Rat Cortical Homogenates and Sections

  1. Casida JE, Palmer CJ, Cole LM (1985) Bicycloorthocarboxylate convulsants. Potent GABAA receptor antagonists. Mol Pharmacol 28:246–253PubMedGoogle Scholar
  2. Gee KW, Lawrence LJ, Yamamura HI (1986) Modulation of the chloride ionophore by benzodiazepine receptor ligands: influence of gamma-aminobutyric acid and ligand efficacy. Mol Pharmacol 30:218–225PubMedGoogle Scholar
  3. Macksay G, Ticku MK (1985a) Dissociation of [35S]-t-butylbicyclophosphorothionate binding differentiates convulsant and depressant drugs that modulate GABAergic transmission. J Neurochem 44:480–486Google Scholar
  4. Macksay G, Ticku MK (1985b) GABA, depressants and chloride ions affect the rate of dissociation of [35S]-t-butyl-bicyclophosphorothionate binding. Life Sci 37:2173–2180Google Scholar
  5. Olsen RW, Yang J, King RG, Dilber A, Stauber GB, Ransom RW (1986) Barbiturate and benzodiazepine modulation of GABA receptor binding and function. Life Sci 39:1969–1976PubMedGoogle Scholar
  6. Squires RF, Casida JE, Richardson M, Saederup E (1983) [35S]t-Butylbicyclophosphorothionate binds with high affinity to brain specific sites coupled to γ-aminobutyric acid-A and ion recognition sites. Mol Pharmacol 23:326–336PubMedGoogle Scholar
  7. Supavilai P, Karabath M (1984) [35S]-t-Butylbicyclophosphorothionate binding sites are constituents of the γ-aminobutyric acid benzodiazepine receptor complex. J Neurosci 4:1193–1200PubMedGoogle Scholar
  8. Trifiletti RR, Snowman AM, Snyder SH (1984) Anxiolytic cyclopyrrolone drugs allosterically modulate the binding of [35S]t-butylbicyclophosphorothionate to the benzodiazepine/γ-aminobutyric acid-A receptor/chloride anionophore complex. Mol Pharmacol 26:470–476PubMedGoogle Scholar
  9. Trifiletti RR, Snowman AM, Snyder SH (1985) Barbiturate recognition site on the GABA/Benzodiazepine receptor complex is distinct from the picrotoxin/TBPS recognition site. Eur J Pharmacol 106:441–447Google Scholar

[3H]glycine Binding in Rat Cerebral Cortex

  1. Baron BM, Harrison BL, Miller FP, McDonald IA, Salituro FG, Schmidt CJ, Sorensen SM, White HS, Palfreyman MG (1990) Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-d-aspartate receptor-associated glycine binding site. Mol Pharmacol 38:554–561PubMedGoogle Scholar
  2. Baron BM, Siegel BW, Harrison BL, Gross RS, Hawes C, Towers P (1996) [3H]MDL 105,519, a high affinity radioligand for the N-methyl-d-aspartate receptor-associated glycine recognition site. J Pharmacol Exp Ther 279:62–68PubMedGoogle Scholar
  3. Becker L, von Wegener J, Schenkel J, Zeilhofer HU, Swandulla D, Weiher H (2002) Disease specific human glycine receptor αl subunit causes hyperekplexia phenotype and impaired glycine and GABAA-receptor transmission in transgenic mice. J Neurosci 22:2505–2512PubMedGoogle Scholar
  4. Bonhaus DW, Burge BC, McNamara JO (1978) Biochemical evidence that glycine allosterically regulates an NMDA receptor-coupled ion channel. Eur J Pharmacol 142:489–490Google Scholar
  5. Bonhaus DW, Yeh G-C, Skaryak L, McNamara JO (1989) Glycine regulation of the N-methyl-d-aspartate receptorgated ion channel in hippocampal membranes. Mol Pharmacol 36:273–279PubMedGoogle Scholar
  6. Chazot PL, Reiss C, Chopra B, Stephenson FA (1998) [3H]MDL 105,519 binds with equal high affinity to both assembled and unassembled NR1 subunits of the NMDA receptor. Eur J Pharmacol 353:137–140PubMedGoogle Scholar
  7. Cotman CW, Monaghan DT, Ottersen OP, Storm-Mathisen J (1987) Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci 10:273–280Google Scholar
  8. Danysz W, Wroblewski JT, Brooker G, Costa E (1989) Modulation of glutamate receptors by phencyclidine and glycine in the rat cerebellum: cGMP increase in vivo. Brain Res 479:270–276PubMedGoogle Scholar
  9. Foster AC, Kemp JA, Leeson PD, Grimwood S, Donald AE, Marshall GR, Priestley T, Smith JD, Carling RW (1992) Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-d-aspartate receptor from rat brain. Mol Pharmacol 41:914–922PubMedGoogle Scholar
  10. Hargreaves RJ, Rigby M, Smith D, Hill RG (1993) Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br J Pharmacol 110:36–42PubMedCentralPubMedGoogle Scholar
  11. Hofner G, Wanner KT (1997) Characterization of the binding of [3H]MDL 105,519, a radiolabelled antagonist for the N-methyl-d-aspartate receptor-associated glycine site to pig cortical brain membranes. Neurosci Lett 226:79–82PubMedGoogle Scholar
  12. Jansen KLR, Dragunow M, Faull RLM (1989) [3H]Glycine binding sites, NMDA and PCP receptors have similar distributions in the human hippocampus: an autoradiographic study. Brain Res 482:174–1178PubMedGoogle Scholar
  13. Kessler M, Terramani T, Lynch B, Baudry M (1989) A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319–1328PubMedGoogle Scholar
  14. Laube B, Maksay G, Schemm R, Betz H (2002) Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses? Trends Pharmacol Sci 23:519–527PubMedGoogle Scholar
  15. Lynch JW (2004) Molecular structure and function of the glycine receptor chloride channel. Physiol Rev 84:1051–1095Google Scholar
  16. Monahan JB, Corpus VM, Hood WF, Thomas JW, Compton RP (1989) Characterization of a [3H]glycine recognition site as a modulatory site of the N-Methyl-d-aspartate receptor complex. J Neurochem 53:370–375PubMedGoogle Scholar
  17. Oliver MW, Kessler M, Larson J, Schottler F, Lynch G (1990) Glycine site associated with the NMDA receptor modulates long-term potentiation. Synapse 5:265–270PubMedGoogle Scholar
  18. Ransom RW, Deschenes NL (1988) NMDA-induced hippocampal [3H]norepinephrine release is modulated by glycine. Eur J Pharmacol 156:149–155PubMedGoogle Scholar
  19. Rao TS, Cler JA, Emmet MR, Mick SJ, Iyengar S, Wood PL (1990) Glycine, glycinamide, and d-serine act as positive modulators of signal transduction at the N-methyl-d-aspartate (NMDA) receptor in vivo: differential effects on mouse cerebellar cyclic guanosine monophosphate levels. Neuropharmacology 29:1075–1080PubMedGoogle Scholar
  20. Rees MI, Lewis TM, Kwok JBJ, Mortier GR, Govaert P, Snell RG, Schofield PR, Owen MJ (2002) Hyperekplexia associated with compound heterozygote mutations in the β-subunit of the human inhibitory glycine receptor. (GLRB). Hum Mol Genet 11:853–860PubMedGoogle Scholar
  21. Reynolds IJ, Murphy SN, Miller RJ (1987)3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci U S A 84:7744–7748PubMedCentralPubMedGoogle Scholar
  22. Sacaan AI, Johnson KM (1989) Spermine enhances binding to the glycine site associated with N-methyl-d-aspartate receptor complex. Mol Pharmacol 36:836–839Google Scholar
  23. Schmieden V, Betz H (1995) Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic compounds. Mol Pharmacol 48:919–927PubMedGoogle Scholar
  24. Snell LD, Morter RS, Johnson KM (1987) Glycine potentiates N-methyl-d-aspartate induced [3H]TCP binding to rat cortical membranes. Neurosci Lett 83:313–317Google Scholar
  25. Snell LD, Morter RS, Johnson KM (1988) Structural requirements for activation of the glycine receptor that modulates the N-methyl-d-aspartate operated ion channel. Eur J Pharmacol 156:105–110Google Scholar
  26. Thomson AM (1989) Glycine modulation of the NMDA receptor/channel complex. Trends Neurosci 12:349–353Google Scholar
  27. White HS, Harmsworth WL, Sofia RD, Wof HH (1995) Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 20:41–48PubMedGoogle Scholar

[3H]strychnine-Sensitive Glycine Receptor

  1. Betz H, Kuhse J, Schmieden V, Laube B, Harvey R (1998) Structure, diversity and pathology of the inhibitory glycine receptor. Naunyn-Schmiedeberg’s Arch Pharmacol 358(Suppl 2):R 570Google Scholar
  2. Braestrup C, Nielsen M, Krogsgaard-Larsen P (1986) Glycine antagonists structurally related to 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol inhibit binding of [3H]strychnine to rat brain membranes. J Neurochem 47:691–696PubMedGoogle Scholar
  3. Bristow DR, Bowery NG, Woodruff GN (1986) Light microscopic autoradiographic localisation of [3H]glycine and [3H]strychnine binding sites in rat brain. Eur J Pharmacol 126:303–307PubMedGoogle Scholar
  4. Bruns RF, Welbaum BEA (1985) A sodium chloride shift method to distinguish glycine agonists from antagonists in [3H]strychnine binding. Fed Proc 44:1828Google Scholar
  5. Graham D, Pfeiffer F, Simler R, Betz H (1985) Purification and characterization of the glycine receptor of pig spinal cord. Biochemistry 24:990–994PubMedGoogle Scholar
  6. Johnson G, Nickell DG, Ortwine D, Drummond JT, Bruns RF, Welbaum BE (1989) Evaluation and synthesis of aminohydroxyisoxazoles and pyrazoles as potential glycine agonists. J Med Chem 32:2116–2128PubMedGoogle Scholar
  7. Johnson G, Drummond JT, Boxer PA, Bruns RF (1992) Proline analogues as agonists at the strychnine-sensitive glycine receptor. J Med Chem 35:233–241PubMedGoogle Scholar
  8. Kishimoto H, Simon JR, Aprison MH (1981) Determination of the equilibrium constants and number of glycine binding sites in several areas of the rat central nervous system, using a sodium-independent system. J Neurochem 37:1015–1024PubMedGoogle Scholar
  9. Lambert DM, Poupaert JH, Maloteaux JM, Dumont P (1994) Anticonvulsant activities of N-benzyloxycarbonylglycine after parenteral administration. NeuroReport 5:777–780PubMedGoogle Scholar
  10. Marvizon JCG, Vázquez J, Calvo MG, Mayor F Jr, Gómez AR, Valdivieso F, Benavides J (1986) The glycine receptor: pharmacological studies and mathematical modeling of the allosteric interaction between the glycine- and strychnine-binding sites. Mol Pharmacol 30:590–597PubMedGoogle Scholar
  11. Saitoh T, Ishida M, Maruyama M, Shinozaki H (1994) A novel antagonist, phenylbenzene-ω-phosphono-a-amino acid, for strychnine-sensitive glycine receptors in the rat spinal cord. Br J Pharmacol 113:165–170PubMedCentralPubMedGoogle Scholar
  12. Schmieden V, Jezequel S, Beth H (1996) Novel antagonists of the inhibitory glycine receptor derived from quinolinic acid compounds. Mol Pharmacol 48:919–927Google Scholar
  13. Simmonds MA, Turner JP (1985) Antagonism of inhibitory amino acids by the steroid derivative RU5135. Br J Pharmacol 84:631–635PubMedCentralPubMedGoogle Scholar
  14. Young AB, Snyder SH (1974) Strychnine binding in rat spinal cord membranes associated with the synaptic glycine receptor: co-operativity of glycine interactions. Mol Pharmacol 10:790–809Google Scholar

Electrical Recordings from Hippocampal Slices in Vitro

  1. Alger BE (1984) Hippocampus. Electrophysiological studies of epileptiform activity in vitro. In: Dingledine R (ed) Brain slices. Plenum Press, New York/London, pp 155–199Google Scholar
  2. Alger BE, Nicoll RA (1982) Pharmacological evidence of two kinds of GABA receptor on rat hippocampal pyramidal cells studied in vitro. J Physiol 328:125–141PubMedCentralPubMedGoogle Scholar
  3. Alger BE, Dhanjal SS, Dingledine R, Garthwaite J, Henderson G, King GL, Lipton P, North A, Schwartzkroin PA, Sears TA, Segal M, Whittingham TS, Williams J (1984) Brain slice methods. In: Dingledine R (ed) Brain slices. Plenum Press, New York/London, pp 381–437Google Scholar
  4. Bernard C, Wheal HV (1995) Plasticity of AMP and NMDA receptor mediated epileptiform activity in a chronic model of temporal lobe epilepsy. Epilepsy Res 21:95–107PubMedGoogle Scholar
  5. Bingmann D, Speckmann EJ (1986) Actions of pentylenetetrazol (PTZ) on CA3 neurons in hippocampal slices of guinea pigs. Exp Brain Res 64:94–104PubMedGoogle Scholar
  6. Blanton MG, Turco JJL, Kriegstein AR (1989) Whole cell recording from neurons in slices of reptilian and mammalian cerebral cortex. J Neurosci Methods 30:203–210PubMedGoogle Scholar
  7. Coan EJ, Saywood W, Collingridge GL (1987) MK-801 blocks NMDA receptor-mediated synaptic transmission and long term potentiation in rat hippocampal slices. Neurosci Lett 80:111–114PubMedGoogle Scholar
  8. Crain SM (1972) Tissue culture models of epileptiform activity. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy – a manual for the laboratory worker. Raven, New York, pp 291–316Google Scholar
  9. Dingledine R, Dodd J, Kelly JS (1980) The in vitro brain slice as a useful neurophysiological preparation for intracellular recording. J Neurosci Methods 2:323–362PubMedGoogle Scholar
  10. Fisher RS (1987) The hippocampal slice. Am J EEG Technol 27:1–14Google Scholar
  11. Fisher RS, Alger BE (1984) Electrophysiological mechanisms of kainic acid-induced epileptiform activity in the rat hippocampal slice. J Neurosci 4:1312–1323PubMedGoogle Scholar
  12. Fredholm BB, Dunwiddie TV, Bergman B, Lindström K (1984) Levels of adenosine and adenine nucleotides in slices of rat hippocampus. Brain Res 295:127–136PubMedGoogle Scholar
  13. Gahwiler BH (1988) Organotypic cultures of neuronal tissue. Trends Neurol Sci 11:484–490Google Scholar
  14. Harrison NL, Simmonds MA (1985) Quantitative studies on some antagonists of N-methyl-d-aspartate in slices of rat cerebral cortex. Br J Pharmacol 84:381–391PubMedCentralPubMedGoogle Scholar
  15. Langmoe IA, Andersen P (1981) The hippocampal slice in vitro. A description of the technique and some examples of the opportunities it offers. In: Kerkut GA, Wheal HV (eds) Electrophysiology of isolated mammalian CNS preparations. Academic, London/New York, pp 51–105Google Scholar
  16. Liu FC, Takahashi H, Mc Kay RDG, Graybiel AM (1995) Dopaminergic regulation of transcription factor expression in organotypic cultures of developing striatum. J Neurosci 15:2367–2384PubMedGoogle Scholar
  17. Misgeld U (1992) Hippocampal slices. In: Kettenmann H, Grantyn R (eds) Practical electrophysiological methods. Wiley, New York, pp 41–44Google Scholar
  18. Mosfeldt Laursen A (1984) The contribution of in vitro studies to the understanding of epilepsy. Acta Neurol Scand 69:367–375PubMedGoogle Scholar
  19. Müller CM (1992) Extra- and intracellular voltage recording in the slice. In: Kettenmann H, Grantyn R (eds) Practical electrophysiological methods. Wiley, New York, pp 249–295Google Scholar
  20. Oh DJ, Dichter MA (1994) Effect of a γ-aminobutyric acid uptake inhibitor, NNC-711, on spontaneous postsynaptic currents in cultured rat hippocampal neurons: implications for antiepileptic drug development. Epilepsia 35:426–430PubMedGoogle Scholar
  21. Okada Y, Ozawa S (1980) Inhibitory action of adenosine on synaptic transmission in the hippocampus of the guinea pig in vitro. Eur J Pharmacol 68:483–492PubMedGoogle Scholar
  22. Oliver AP, Hoffer BJ, Wyatt RJ (1977) The hippocampal slice: a model system for studying the pharmacology of seizures and for screening of anticonvulsant drugs. Epilepsia 18:543–548PubMedGoogle Scholar
  23. Pandanaboina MM, Sastry BR (1984) Rat neocortical slice preparation for electrophysiological and pharmacological studies. J Pharmacol Methods 11:177–186PubMedGoogle Scholar
  24. Saltarelli MD, Lowenstein PR, Coyle JT (1987) Rapid in vitro modulation of [3H]hemicholinium-3 binding sites in rat striatal slices. Eur J Pharmacol 135:35–40PubMedGoogle Scholar
  25. Schlicker E, Fink K, Zentner J, Göthert M (1996) Presynaptic inhibitory serotonin autoreceptors in the human hippocampus. Naunyn-Schmiedeberg’s Arch Pharmacol 354:393–396Google Scholar
  26. Schwartzkroin PA (1975) Characteristics of CA1 neurons recorded intracellularly in the hippocampal in vitro slice preparation. Brain Res 85:423–436PubMedGoogle Scholar
  27. Siggins GR, Schubert P (1981) Adenosine depression of hippocampal neurons in vitro: an intracellular study of dose-dependent actions on synaptic and membrane potentials. Neurosci Lett 23:55–60PubMedGoogle Scholar
  28. Skrede KK, Westgard RH (1971) The transverse hippocampal slice: a well-defined cortical structure maintained in vitro. Brain Res 35:589–659PubMedGoogle Scholar
  29. Stoppini L, Buchs PA, Muller D (1991) A simple method for oganotypic cultures of nervous tissue. J Neurosci Methods 37:173–182PubMedGoogle Scholar
  30. Stuart GJ, Dodt HU, Sakmann B (1993) Patch-clamp recordings from the soma and dendrites of neurons in brain slices using infrared video microscopy. Pflugers Arch 423:511–518PubMedGoogle Scholar
  31. Teyler TT (1980) Brain slice preparation: hippocampus. Brain Res Bull 5:391–403PubMedGoogle Scholar

Electrical Recordings from Isolated Nerve Cells

  1. Banker GA, Cowan WM (1977) Rat hippocampal neurons in dispersed cell culture. Brain Res 126:397–425Google Scholar
  2. Caulfield MP, Brown DA (1992) Cannabinoid receptor agonists inhibit Ca current in NG108–15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106:231–232PubMedCentralPubMedGoogle Scholar
  3. Chen Q-X, Stelzer A, Kay AR, Wong RKS (1990) GABAA receptor function is regulated by phosphorylation in acutely dissociated guinea-pig hippocampal neurones. J Physiol 420:207–221PubMedCentralPubMedGoogle Scholar
  4. Delmas P, Brown DA, Dayrell M, Abogadie FC, Caulfield MP, Buckley NJ (1998) On the role of endogenous G-protein β γ subunits in N-type Ca2+ current inhibition by neurotransmitters in rat sympathetic neurones. J Physiol 506:319–329PubMedCentralPubMedGoogle Scholar
  5. Gola M, Niel JP (1993) Electrical and integrative properties of rabbit sympathetic neurons re-evaluated by patch-clamping non-dissociated cells. J Physiol 460:327–349PubMedCentralPubMedGoogle Scholar
  6. Gola M, Niel JP, Bessone R, Fayolle R (1992) Single channel and whole cell recordings from non dissociated sympathetic neurones in rabbit coeliac ganglia. J Neurosci Methods 43:13–22PubMedGoogle Scholar
  7. Gonzales F, Farbman AI, Gesteland RC (1985) Cell and explant culture of olfactory chemoreceptor cells. J Neurosci Methods 14:77–90PubMedGoogle Scholar
  8. Jirikowski G, Reisert I, Pilgrim C (1981) Neuropeptides in dissociated cultures of hypothalamus and septum; quantification of immunoreactive neurons. Neuroscience 6:1953–1960Google Scholar
  9. Kay AR, Wong RKS (1986) Isolation of neurons suitable for patch-clamping from adult mammalian central nervous systems. J Neurosci Methods 16:227–238PubMedGoogle Scholar
  10. McGivern JG, Patmore L, Sheridan RD (1995) Actions of the novel neuroprotective agent, lifarizine (RS-87476), on voltage- dependent sodium currents in the neuroblastoma cell line, NIE-115. Br J Pharmacol 114:1738–1744PubMedCentralPubMedGoogle Scholar
  11. McLarnon JG (1991) The recording of action potential currents as an assessment for drug actions on excitable cells. J Pharmacol Methods 26:105–111PubMedGoogle Scholar
  12. McLarnon JG, Curry K (1990) Single channel properties of the N-methyl-d-aspartate receptor channel using NMDA and NMDA agonists: on-cell recordings. Exp Brain Res 82:82–88PubMedGoogle Scholar
  13. Neher E, Sakmann B (1976) Single-channel currents recorded from membrane of denervated frog muscle fibres. Nature 260:799–802PubMedGoogle Scholar
  14. Sakmann B, Neher E (1983) Single channel recording. Plenum Press, New YorkGoogle Scholar
  15. Smith PA (1995) Methods for studying neurotransmitter transduction mechanisms. J Pharmacol Toxicol Methods 33:63–73PubMedGoogle Scholar
  16. Stolc S (1994) Pyridoindole stobadine is a nonselective inhibitor of voltage-operated ion channels in rat sensory neurons. Gen Physiol Biophys 13:259–266PubMedGoogle Scholar

Isolated Neonatal Rat Spinal Cord

  1. Akagi H, Konishi S, Otsuka M, Yanagisawa M (1985) The role of substance P as a neurotransmitter in the reflexes of slow time courses in the neonatal rat spinal cord. Br J Pharmacol 84:663–673PubMedCentralPubMedGoogle Scholar
  2. Bleakman D, Rusin KI, Chard PS, Glaum SR, Miller RJ (1992) Metabotropic glutamate receptors potentiate ionotropic glutamate responses in the rat dorsal horn. Mol Pharmacol 42:192–196PubMedGoogle Scholar
  3. Boxall SJ, Thompson SWN, Dray A, Dickenson AH, Urban L (1996) Metabotropic glutamate receptor activation contribute to nociceptive reflex activity in the rat spinal cord in vitro. Neuroscience 74:13–20PubMedGoogle Scholar
  4. Dong X-W, Morin D, Feldman JL (1996) Multiple actions of 1S, 3R-ACPD in modulating endogenous synaptic transmission to spinal respiratory motoneurons. J Neurosci 16:4971–4982PubMedGoogle Scholar
  5. Evans RH, Francis AA, Jones AW, Smith DAS, Watkins JC (1982) The effects of a series of ω-phosphonic α-carboxylic amino acids on electrically evoked and excitant amino-acid-induced responses in isolated spinal cord preparations. Br J Pharmacol 75:65–75PubMedCentralPubMedGoogle Scholar
  6. Faber ESL, Chambers JP, Brugger F, Evans RH (1997) Depression of A and C fibre-evoked segmental reflexes by morphine and clonidine in the in vitro spinal cord of the neonatal rat. Br J Pharmacol 120:1390–1396PubMedCentralPubMedGoogle Scholar
  7. Guo JZ, Yoshioka K, Otsuka M (1998) Effects of a tachykinin NK3 receptor antagonist, SR 142801, studied in isolated neonatal spinal cord. Neuropeptides 32:537–542PubMedGoogle Scholar
  8. Ishida M, Shinozakai H (1991) Novel kainate derivatives: potent depolarizing actions on spinal motoneurons and dorsal root fibres in newborn rats. Br J Pharmacol 104:873–878PubMedCentralPubMedGoogle Scholar
  9. Ishida M, Akagi H, Shimamoto K, Ohfune Y, Shinozaki H (1990) A potent metabotropic glutamate receptor agonist: electrophysiological actions of a conformationally restricted glutamate analogue in the rat spinal cord and Xenopus oocytes. Brain Res 537:311–314Google Scholar
  10. Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (1993) A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord. Br J Pharmacol 109:1169–1177PubMedCentralPubMedGoogle Scholar
  11. Jane DE, Jones PLSJ, Pook PCK, Tse HW, Watkins JC (1994) Actions of two new antagonists showing selectivity for different subtypes of metabotropic glutamate receptor in the neonatal rat spinal cord. Br J Pharmacol 112:809–816Google Scholar
  12. Kendig JJ, Savola MKT, Woodley SJ, Maze M (1991) α 2-adrenoceptors inhibit a nociceptive response in neonatal rat spinal cord. Eur J Pharmacol 192:293–300PubMedGoogle Scholar
  13. King AE, Lopez-Garcia JA, Cumberbatch M (1992) Antagonism of synaptic potentials in ventral horn neurons by 6-cyano-7-nitroquninoxaline-2,3-dione: a study in the rat spinal cord in vitro. Br J Pharmacol 107:375–381PubMedCentralPubMedGoogle Scholar
  14. Lev-Tov A, Pinco M (1992) In vitro studies of prolonged synaptic depression in the neonatal rat spinal cord. J Physiol 447:149–169PubMedCentralPubMedGoogle Scholar
  15. Nussbaumer JC, Yanagisawa M, Otsuka M (1989) Pharmacologic properties of a C fibre response evoked by saphenous nerve stimulation in an isolated spinal cord-nerve preparation of the newborn rat. Br J Pharmacol 98:373–382PubMedCentralPubMedGoogle Scholar
  16. Ohno Y, Warnick JE (1988) Effects of thyrotropin-releasing hormone on phencyclidine- and ketamine-induced spinal depression in neonatal rats. Neuropharmacology 27:1013–1018PubMedGoogle Scholar
  17. Ohno Y, Warnick JE (1990) Selective depression of the segmental polysynaptic reflex by phencyclidine and its analogs in the rat in vitro: Interaction with N-methyl-d-aspartate receptors. J Pharmacol Exp Ther 252:246–252PubMedGoogle Scholar
  18. Otsuka M, Konishi S (1974) Electrophysiology of mammalian spinal cord in vitro. Nature 252:733–734PubMedGoogle Scholar
  19. Otsuka M, Yanagisawa M (1988) Effect of a tachykinin antagonist on a nociceptive reflex in the isolated spinal cord tail preparation of the newborn rat. J Physiol 395:255–270PubMedCentralPubMedGoogle Scholar
  20. Pook P, Brugger F, Hawkins NS, Clark KC, Watkins JC, Evans RH (1993) A comparison of action of agonists and antagonists at non-NMDA receptors of C fibres and motoneurons of the immature rat spinal cord in vitro. Br J Pharmacol 108:179–184PubMedCentralPubMedGoogle Scholar
  21. Shinozaki H, Ishida M, Shimamoto K, Ohfune Y (1989) Potent NMDA-like actions and potentiation of glutamate responses by conformational variants of a glutamate analogue in the rat spinal cord. Br J Pharmacol 98:1213–1224PubMedCentralPubMedGoogle Scholar
  22. Smith JC, Feldman JL (1987) In vitro brainstem-spinal cord preparations for study of motor systems for mammalian respiration and locomotion. J Neurosci Methods 21:321–333PubMedGoogle Scholar
  23. Thompson SWN, Gerber G, Sivilotti LG, Woolf CJ (1992) Long duration of ventral root potentials in the neonatal spinal cord in vitro: the effects of ionotropic and metabotropic excitatory amino acid receptor antagonists. Brain Res 595:87–97PubMedGoogle Scholar
  24. Woodley SJ, Kendig JJ (1991) Substance P and NMDA receptors mediate a slow nociceptive ventral root potential in neonatal rat spinal cord. Brain Res 559:17–22PubMedGoogle Scholar
  25. Yanagisawa M, Otsuka M, Konishi S, Akagi H, Folkers K, Rosell S (1982) A substance P antagonist inhibits a slow reflex response in the spinal cord of the newborn rat. Acta Physiol Scand 116:109–112PubMedGoogle Scholar
  26. Yanagisawa MT, Murakoshi T, Tamai S, Otsuka M (1985) Tailpinch method in vitro and the effect of some antinociceptive compounds. Eur J Pharmacol 106:231–239Google Scholar
  27. Zeman S, Lodge D (1992) Pharmacological characterization of non-NMDA subtypes of glutamate receptor in the neonatal rat hemisected spinal cord in vitro. Br J Pharmacol 106:367–372Google Scholar

Cell Culture of Neurons

  1. Araujo DM, Cotman CW (1993) Trophic effects of interleukin-4, -7, and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. Brain Res 600:49–55PubMedGoogle Scholar
  2. Banker GA, Cowan WM (1977) Rat hippocampal neurons in dispersed cell culture. Brain Res 126:397–425Google Scholar
  3. Brewer GJ (1997) Isolation and culture of adult hippocampal neurons. J Neurosci Methods 71:143–155PubMedGoogle Scholar
  4. Brewer GJ (1999) Regeneration and proliferation of embryonic and adult rat hippocampal neurons in culture. Exp Neurol 159:237–247PubMedGoogle Scholar
  5. Brewer GJ, Deshmane S, Ponnusamy E (1998) Precocious axons and improved survival of rat hippocampal neurons on lysine-alanine polymer substrate. J Neurosci Methods 85:13–20PubMedGoogle Scholar
  6. Canals S, Casarejos MJ, Rodríguez-Martin E, de Bernardo S, Mena MA (2001) Neurotrophic and neurotoxic effects of nitric oxide on fetal midbrain cultures. J Neurochem 76:56–68PubMedGoogle Scholar
  7. Chaudieu I, Privat A (1999) Neuroprotection of cultured foetal rat hippocampal cells against glucose deprivation: are GABAergic neurons less vulnerable or more sensitive to TCP protection? Eur J Neurosci 11:2413–2421PubMedGoogle Scholar
  8. Ehret A, Haaf A, Jeltsch H, Heinrich B, Feuerstein TJ, Jakisch R (2001) Modulation of electrically evoked acetylcholine release in cultured septal neurones. J Neurochem 76:555–564PubMedGoogle Scholar
  9. Flavin MP, Ho LT (1999) Propentofylline protects neurons in culture from death triggered by macrophage or microglia secretory products. J Neurosci Res 56:54–59PubMedGoogle Scholar
  10. Hampson RE, Mu J, Deadwyler SA (2000) Cannabinoid and kappa opioid receptors reduced potassium K current via activation of Gs proteins in cultured hippocampal neurons. J Neurophysiol 84:2356–2364PubMedGoogle Scholar
  11. Jirikowski G, Reisert I, Pilgrim Ch (1981) Neuropeptides in dissociated cultures of hypothalamus and septum: quantitation of immunoreactive neurons. Neuroscience 6:1953–1960Google Scholar
  12. Li YX, Zhang Y, Lester HA, Schuman EM, Davidson N (1998) Enhancement of neurotransmitter release induced by brain-derived neurotrophic factor in cultured hippocampal neurons. J Neurosci 18:10231–10240PubMedGoogle Scholar
  13. López E, Arce C, Vicente S, Oset-Gasque MJ, González MP (2001) Nicotinic receptors mediate the release of amino acid neurotransmitters in cultured cortical neurons. Cereb Cortex 11:158–163PubMedGoogle Scholar
  14. May PC, Robison PM, Fuson KS (1999) Stereoselective neuroprotection by a novel 2,3-benzodiazepine non-competitive AMPA antagonist against non-NMDA receptor mediated excitotoxicity in primary rat hippocampal culture. Neurosci Lett 262:219–221PubMedGoogle Scholar
  15. Mitoma J, Ito M, Furuya S, Hirabayashi Y (1998) Bipotential roles of ceramide in the growth of hippocampal neurones: promotion of cell survival and dendritic outgrowth in dose and developmental stage-dependent manners. J Neurosci Res 51:712–722PubMedGoogle Scholar
  16. Noh K-M, Koh J-Y (2000) Induction and activation by zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J Neurosci 20:RC111, 1–5PubMedGoogle Scholar
  17. Novitskaya V, Grigorian M, Kriajevska M, Tarabykina S, Bronstein I, Berezin V, Bock E, Lukanidin E (2000) Oligomeric forms of the metastasis-related Mts1 (S100A4) protein stimulate neuronal differentiation in cultures of rat hippocampal neurons. J Biol Chem 275:41278–41286PubMedGoogle Scholar
  18. Pickard L, Noël J, Henley JM, Collingridge GL, Molnar E (2000) Developmental changes in synaptic AMPA and NMDA receptor distribution and AMPA receptor subunit composition in living hippocampal neurons. J Neurosci 20:7922–7931PubMedGoogle Scholar
  19. Saluja I, Granneman JG, Skoff RP (2001) PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33:191–204PubMedGoogle Scholar
  20. Semkowa I, Wolz P, Krieglstein J (1998) Neuroprotective effect of 5-HT1A receptor agonist, Bay X 3702, demonstrated in vitro and in vivo. Eur J Pharmacol 359:251–260Google Scholar
  21. Semkowa I, Häberlein C, Krieglstein J (1999) Ciliary neurotrophic factor protects hippocampal neurons from excitotoxic damage. Neurochem Int 35:1–10Google Scholar
  22. Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E (2000) NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurones in vitro. J Neurosci 20:8831–8837PubMedGoogle Scholar
  23. Skaper SD, Facci L, Milani L, Leon A, Toffano G (1990) Culture and use of primary and clonal neural cells. In: Conn PM (ed) Methods in neuroscience, vol 2. Academic, San Diego, pp 17–33Google Scholar
  24. Skaper SD, Leon A, Facci L (1993) Basic fibroblast growth factor modulates sensitivity of cultured hippocampal pyramidal neurones to glutamate cytotoxicity: interaction with ganglioside GM1. Brain Res Dev Brain Res 71:1–8PubMedGoogle Scholar
  25. Skaper SD, Facci L, Kee WJ, Strijbös PJLM (2001) Potentiation by histamine of synaptically mediated excitotoxicity in cultured hippocampal neurones: a possible role for mast cells. J Neurochem 76:47–55PubMedGoogle Scholar
  26. Tang DG, Tokumoto YM, Apperly JA, Lloyd AC, Raff MC (2001) Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. Science 291:868–871PubMedGoogle Scholar
  27. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL (2000) Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 97:14720–14725PubMedCentralPubMedGoogle Scholar
  28. Vergun O, Sobolevsky AI, Yelshansky MV, Keelan J, Khodorov BI, Duchen MR (2001) Exploration of the role of reactive oxygen species in glutamate neurotoxicity in rat hippocampal neurons in culture. J Physiol 531:147–163PubMedCentralPubMedGoogle Scholar
  29. Yamagishi S, Yamada M, Ishikawa Y, Matsumoto T, Ikeuchi T, Hatanaka H (2001) p38 Mitogen-activated protein kinase regulates low potassium-induced c-Jun phosphorylation and apoptosis in cultured cerebellar granule neurons. J Biol Chem 276:5129–5133PubMedGoogle Scholar

Electroshock in Mice

  1. Cashin CH, Jackson H (1962) An apparatus for testing anticonvulsant drugs by electroshock seizures in mice. J Pharm Pharmacol 14:445–475Google Scholar
  2. Kitano Y, Usui C, Takasuna K, Hirohashi M, Nomura M (1996) Increasing-current electroshock seizure test: a new method for assessment of anti- and pro-convulsant activities of drugs in mice. J Pharmacol Toxicol Methods 35:25–29PubMedGoogle Scholar
  3. Löscher W, Stephens DN (1988) Chronic treatment with diazepam or the inverse benzodiazepine receptor agonist FG 7142 causes different changes in the effects of GABA receptor stimulation. Epilepsy Res 2:253–259PubMedGoogle Scholar
  4. Rastogi SA, Ticku MK (1985) Involvement of a GABAergic mechanism in the anticonvulsant effect of phenobarbital against maximal electroshock-induced seizures in rats. Pharmacol Biochem Behav 222:141–146Google Scholar
  5. Sohn YJ, Levitt B, Raines A (1970) Anticonvulsive properties of diphenylthiohydantoin. Arch Int Pharmacodyn 188:284–289PubMedGoogle Scholar
  6. Swinyard EA (1972) Electrically induced convulsions. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy – a manual for the laboratory worker. Raven, New York, pp 433–458Google Scholar
  7. Swinyard EA, Brown WC, Goodman LS (1952) Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106:319–330PubMedGoogle Scholar
  8. Toman JEP (1964) Animal techniques for evaluating anticonvulsants. In: Nodin JH, Siegler PE (eds) Animal and clinical techniques in drug evaluation, vol 1. Year Book Medical Publishers, Chicago, pp 348–352Google Scholar
  9. Toman JEP, Everett GM (1964) Anticonvulsants. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities: pharmacometrics. Academic, London, New York, pp 287–300Google Scholar
  10. Turner RA (1965) Anticonvulsants. Academic, New York/London, pp 164–172Google Scholar
  11. Woodbury LA, Davenport VO (1952) Design and use of a new electroshock seizure apparatus and analysis of factors altering seizure threshold and pattern. Arch Int Pharmacodyn 92:97–107PubMedGoogle Scholar

Isoniazid-Induced Convulsions in Mice

  1. Hahn F, Oberdorf A (1960) Vergleichende Untersuchungen über die Krampfwirkung von Begrimid, Pentetrazol und Pikrotoxin. Arch Int Pharmacodyn 135:9–30Google Scholar
  2. Leander JD, Lawson RR, Ornstein PL, Zimmerman DM (1988) N-methyl-d-aspartic acid induced lethality in mice: selective antagonism by phencyclidine-like drugs. Brain Res 448:115–120PubMedGoogle Scholar
  3. Pollack GM, Shen DD (1985) A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. J Pharmacol Methods 13:135–146PubMedGoogle Scholar
  4. Shouse MN, Siegel JM, Wu MF, Szymusiak R, Morrison AR (1989) Mechanism of seizure suppression during rapid-eye-movement (REM) sleep in cats. Brain Res 505:271–282PubMedGoogle Scholar
  5. Snead OC III (1988) γ-Hydroxybutyrate model of generalized absence seizures: further characterization and comparison with other absence models. Epilepsia 29:361–368PubMedGoogle Scholar
  6. Stone WE (1972) Systemic chemical convulsants and metabolic derangements. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy – a manual for the laboratory worker. Raven, New York, pp 407–432Google Scholar
  7. Testa R, Graziani L, Graziani G (1983) Do different anticonvulsant tests provide the same information concerning the profiles of antiepileptic activity? Pharmacol Res Commun 15:765–774PubMedGoogle Scholar
  8. Toussi HR, Schatz RAS, Waszczak BL (1987) Suppression of methionine sulfoximine seizures by intranigral γ -vinyl GABA injection. Eur J Pharmacol 137:261–264PubMedGoogle Scholar
  9. Tursky WA, Cavalheiro EA, Coimbra C, da Penha Berzaghi M, Ikonomidou-Turski C, Turski L (1987) Only certain antiepileptic drugs prevent seizures induced by pilocarpine. Brain Res Rev 12:281–305Google Scholar

Bicuculline Test in Rats

  1. Buckett WR (1981) Intravenous bicuculline test in mice: characterisation with GABAergic drugs. J Pharmacol Methods 5:35–41PubMedGoogle Scholar
  2. Clineschmidt BV, Martin GE, Bunting PR (1982) Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:123–134Google Scholar
  3. Czuczwar SJ, Frey HH, Löscher W (1985) Antagonism of N-methyl-d, l-aspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur J Pharmacol 108:273–280PubMedGoogle Scholar
  4. Lloyd KG, Morselli PL (1987) Psychopharmacology of GABAergic drugs. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York pp 183–195Google Scholar
  5. Mecarelli O, de Feo MR, Rina MF, Ricci GF (1988) Effects of progabide on bicuculline-induced epileptic seizures in developing rats. Clin Neuropharmacol 11:443–453PubMedGoogle Scholar

4-Aminopyridine-Induced Seizures in Mice

  1. Morales-Villagran A, Urena-Guerrero ME, Tapia R (1996) Protection by NMDA receptor antagonists against seizures induced by intracerebral administration of 4-aminopyridine. Eur J Pharmacol 305:87–93PubMedGoogle Scholar
  2. Rogawski MA, Porter RJ (1990) Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42:223–286Google Scholar
  3. Rutecki PA, Lebeda FJ, Johnston D (1987) 4-aminopyridine produces epileptiform activity in hippocampus and enhances synaptic excitation and inhibition. J Neurophysiol 57:1911–1924PubMedGoogle Scholar
  4. Schaefer EW Jr, Brunton RB, Cunningham DJ (1973) A summary of the acute toxicity of 4-aminopyridine to birds and mammals. Toxicol Appl Pharmacol 26:532–538Google Scholar
  5. Yamaguchi SI, Rogawski MA (1992) Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 11:9–16PubMedGoogle Scholar

3-Nitropropionic Acid-Induced Seizures in Mice

  1. Alston TA, Mela L, Bright HL (1977) 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci U S A 74:3767–3771PubMedCentralPubMedGoogle Scholar
  2. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M (1991) 3-Nitropropionic acid – exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18:492–498PubMedGoogle Scholar
  3. Urbańska EM, Blaszczak P, Saran T, Kleinrok Z, Turski WA (1998) Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice. Eur J Pharmacol 359:55–58PubMedGoogle Scholar
  4. Urbańska EM, Blaszczak P, Saran T, Kleinrok Z, Turski WA (1999) AMPA/kainate-related mechanisms contribute to convulsant and proconvulsant effects of 3-nitropropionic acid. Eur J Pharmacol 370:251–256PubMedGoogle Scholar
  5. Zuchora B, Wielosz M, Urbańska EM (2005) Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice. Eur Neuropsychopharmacol 15:85–93PubMedGoogle Scholar

Epilepsy Induced by Focal Lesions

  1. Albe-Fessard D, Stutinsky F, Libouban S (1971) Atlas Stéréotaxique du Diencéphale du Rat Blanc. C.N.R.S., ParisGoogle Scholar
  2. Anderer P, Barbanoj MJ, Saletu B, Semlitsch HV (1993) Restriction to a limited set of EEG-target variables may lead to misinterpretation of pharmaco-EEG results. Neuropsychobiology 27:112–116PubMedGoogle Scholar
  3. Atsev E, Yosiphov T (1969) Changes in evoked perifocal electrical activity with an acute epileptogenic focus in cat’s cortex. Electroencephalogr Clin Neurophysiol 27:444Google Scholar
  4. Bernhard CG, Bohm E (1955) The action of local anaesthetics on experimental epilepsy in cats and monkeys. Br J Pharmacol 10:288–295Google Scholar
  5. Bernhard CG, Bohm E, Wiesel T (1956) On the evaluation of the anticonvulsive effect of local anaesthetics. Arch Int Pharmacodyn 108:392–407PubMedGoogle Scholar
  6. Black RG, Abraham J, Ward AA Jr (1967) The preparation of tungstic acid gel and its use in the production of experimental epilepsy. Epilepsia 8:58–63PubMedGoogle Scholar
  7. Blum B, Liban E (1960) Experimental basotemporal epilepsy in the cat. Discrete epileptogenic lesions produced in the hippocampus or amygdaloid by tungstic acid. Neurology 10:546–554PubMedGoogle Scholar
  8. Campell AM, Holmes O (1984) Bicuculline epileptogenesis in the rat. Brain Res 323:239–246Google Scholar
  9. Cavalheiro EA, Riche DA, Gal L, la Salle G (1982) Long-term effects of intrahippocampal kainic acid injections in rats: a method for inducing spontaneous recurrent seizures. Electroencephalogr Clin Neurophysiol 53:581–589PubMedGoogle Scholar
  10. Daniels JC, Spehlman R (1973) The convulsant effect of topically applied atropine. Electroencephalogr Clin Neurophysiol 34:83–87PubMedGoogle Scholar
  11. Dow RS, Fernández-Guardiola A, Manni E (1962) The production of cobalt experimental epilepsy in the rat. Electroencephalogr Clin Neurophysiol 14:399–407PubMedGoogle Scholar
  12. Ferguson JH, Jasper HH (1971) Laminar DC studies of acetylcholine-activated epileptiform discharge in cerebral cortex. Electroencephalogr Clin Neurophysiol 30:377–390PubMedGoogle Scholar
  13. Feria-Velasco A, Olivares N, Rivas F, Velasco M, Velasco F (1980) Alumina cream-induced focal motor epilepsy in cats. Arch Neurol 37:287–290PubMedGoogle Scholar
  14. Fischer J, Holubar J, Malik V (1967) A new method of producing chronic epileptogenic cortical foci in the rat. Physiol Bohemoslov 16:272–277PubMedGoogle Scholar
  15. Hanna GR, Stalmaster RM (1973) Cortical epileptic lesions produced by freezing. Neurology 23:918–925PubMedGoogle Scholar
  16. Hawkins CA, Mellanby JH (1987) Limbic epilepsy induced by tetanus toxin: a longitudinal electroencephalographic study. Epilepsia 28:431–444PubMedGoogle Scholar
  17. Karpiak SE, Graf L, Rapport MM (1976) Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 194:735–737PubMedGoogle Scholar
  18. Karpiak SE, Mahadik SP, Graf L, Rapport MM (1981) An immunological model of epilepsy: seizures induced by antibodies to GM1 ganglioside. Epilepsia 22:189–196PubMedGoogle Scholar
  19. Kopeloff LM, Barrera SE, Kopeloff N (1942) Recurrent convulsive seizures in animals produced by immunologic and chemical means. Am J Psychiatry 98:881–902Google Scholar
  20. Kopeloff L, Chusid JG, Kopeloff N (1955) Epilepsy in Maccaca mulatta after cortical or intracerebral alumina. Arch Neurol Psychiatry 74:523–526Google Scholar
  21. Krupp E, Löscher W (1998) Anticonvulsant drug effects in the direct cortical ramp-stimulation model in rats: comparison with convulsive seizure models. J Pharmacol Exp Ther 285:1137–1149PubMedGoogle Scholar
  22. Lange SC, Neafsey EJ, Wyler AR (1980) Neuronal activity in chronic ferric chloride epileptic foci in cats and monkey. Epilepsia 21:251–254PubMedGoogle Scholar
  23. Loiseau H, Avaret N, Arrigoni E, Cohadon F (1987) The early phase of cryogenic lesions: an experimental model of seizures updated. Epilepsia 28:251–258PubMedGoogle Scholar
  24. Marsan CA (1972) Focal electrical stimulation. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy – a manual for the laboratory worker. Raven, New York, pp 147–172Google Scholar
  25. Matsumoto H, Marsan CA (1964) Cortical cellular phenomena in experimental epilepsy: interictal manifestations. Exp Neurol 9:286–304PubMedGoogle Scholar
  26. Mellanby J, Hawkins C, Mellanby H, Rawlins JNP, Impey ME (1984) Tetanus toxin as a tool for studying epilepsy. J Physiol Paris 79:207–215PubMedGoogle Scholar
  27. Pei Y, Zhao D, Huang J, Cao L (1983) Zinc-induced seizures: a new experimental model of epilepsy. Epilepsia 24:169–176PubMedGoogle Scholar
  28. Racine RJ (1972) Modification of seizure activity by electrical stimulation: I. After-discharge threshold. Electroencephalogr Clin Neurophysiol 32:269–279Google Scholar
  29. Reid SA, Sypert GW, Boggs WM, Wilmore LJ (1979) Histopathology of the ferric-induced chronic epileptic focus in cat: a Golgi study. Exp Neurol 66:205–219PubMedGoogle Scholar
  30. Remler MP, Marcussen WH (1986) Systemic focal epileptogenesis. Epilepsia 27:35–42PubMedGoogle Scholar
  31. Remler MP, Sigvardt K, Marcussen WH (1986) Pharmacological response of systemically derived focal epileptic lesions. Epilepsia 27:671–6777PubMedGoogle Scholar
  32. Stalmaster RM, Hanna GR (1972) Epileptic phenomena of cortical freezing in the cat: persistent multifocal effects of discrete superficial lesions. Epilepsia 13:313–324PubMedGoogle Scholar
  33. Turski WA, Czuczwar SJ, Kleinrok Z, Turski L (1983) Cholinomimetics produce seizures and brain damage in rats. Experientia 39:1408–1411PubMedGoogle Scholar
  34. Walton NY, Treiman DM (1989) Phenobarbital treatment of status epilepticus in a rodent model. Epilepsy Res 4:216–222PubMedGoogle Scholar
  35. Walton NY, Gunnawan S, Treiman DM (1994) Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine. Epilepsy Res 19:237–244Google Scholar
  36. Ward AA Jr (1972) Topical convulsant metals. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy – a manual for the laboratory worker. Raven, New York, pp 13–35Google Scholar

Kindled Rat Seizure Model

  1. Babington RG (1975) Antidepressives and the kindling effect. In: Fielding S, Lal H (eds) Antidepressants, vol 2, Industrial pharmacology. Futura Publishing Company, New York, pp 113–124Google Scholar
  2. Croucher MJ, Cotterell KL, Bradford HF (1996) Characterization of N-methyl-d-aspartate (NMDA)-induced kindling. Biochem Soc Transact 24:295SGoogle Scholar
  3. Durmuller N, Craggs M, Meldrum BS (1994) The effect of the non-NMDA receptor antagonists GYKI 52446 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res 17:167–174PubMedGoogle Scholar
  4. Ebert U, Löscher W (1999) Characterization of phenytoin-resistant kindled rats, a new model of drug-resistant epilepsy: influence of genetic factors. Epilepsy Res 33:217–226PubMedGoogle Scholar
  5. Ebert U, Cramer S, Löscher W (1997) Phenytoin’s effect on the spread of seizures in the amygdala kindling model. Naunyn-Schmiedebergs Arch Pharmacol 356:341–347PubMedGoogle Scholar
  6. Gal L, la Salle G (1981) Amygdaloid kindling in the rat: regional differences and general properties. In: Wada JA (ed) Kindling 2. Raven, New York, pp 31–47Google Scholar
  7. Gilbert ME (1994) The phenomenology of limbic kindling. Toxicol Ind Health 10:4–5Google Scholar
  8. Girgis M (1981) Kindling as a model for limbic epilepsy. Neuroscience 6:1695–1706PubMedGoogle Scholar
  9. Goddard GV (1967) Development of epileptic seizures through brain stimulation at low intensity. Nature 214:1020–1021PubMedGoogle Scholar
  10. Goddard GV, McIntyre DC, Leech CK (1969) A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 25:295–330PubMedGoogle Scholar
  11. Goddard GV, Dragunow M, Maru E, Macleod EK (1986) Kindling and the forces that oppose it. In: Doane BK, Livingston KE (eds) The limbic system: functional organization and clinical disorders. Raven, New York, pp 95–108Google Scholar
  12. Heit MC, Schwark WS (1987) An efficient method for time course studies of antiepileptic drugs using the kindled rat seizure model. J Pharmacol Methods 18:319–325PubMedGoogle Scholar
  13. Hoenack D, Loescher W (1989) Amygdala-kindling as a model for chronic efficacy studies on antiepileptic drugs: experiments with carbamazepine. Neuropharmacology 28:599–610Google Scholar
  14. Koella WP (1985) Animal experimental methods in the study of antiepileptic drugs, Chapter 12. In: Frey HH, Danz D (eds) Antiepileptic drugs. Springer, Heidelberg/New York/Tokyo, pp 283–339Google Scholar
  15. Löscher W (1998) Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol 54:721–741Google Scholar
  16. Löscher W, Nolting B, Hönack D (1988) Evaluation of CPP, a selective NMDA antagonist, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital. Eur J Pharmacol 152:9–17PubMedGoogle Scholar
  17. Löscher W, Rundfeldt C, Honack D (1993) Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res 15:207–219PubMedGoogle Scholar
  18. Lothman EW, Salerno RA, Perlin JB, Kaiser DL (1988) Screening and characterization of anti-epileptic drugs with rapidly recurring hippocampal seizures in rats. Epilepsy Res 2:367–379PubMedGoogle Scholar
  19. Mason CR, Cooper RM (1972) A permanent change in convulsive threshold in normal and brain-damaged rats with repeated small doses of pentylenetetrazol. Epilepsia 13:663–674PubMedGoogle Scholar
  20. McNamara JO (1984) Kindling: an animal model of complex partial epilepsy. Ann Neurol 16(Suppl):S72–S76PubMedGoogle Scholar
  21. McNamara JO (1986) Kindling model of epilepsy, Chapter 14. In: Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ (eds) Basic mechanisms of the epilepsies. Molecular and cellular approaches, vol 44, Advances in neurology. Raven, New York, pp 303–318Google Scholar
  22. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) A stereotactic atlas of the brain, 2nd edn. Plenum Press, New YorkGoogle Scholar
  23. Pinel JPJ, Rovner LI (1978) Experimental epileptogenesis: kindling-induced epilepsy in rats. Exp Neurol 58:190–202PubMedGoogle Scholar
  24. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin Neurophysiol 32:281–294Google Scholar
  25. Racine R (1978) Kindling: the first decade. Neurosurgery 3:234–252PubMedGoogle Scholar
  26. Schmidt J (1990) Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. Biomed Biochim Acta 49:413–419PubMedGoogle Scholar
  27. Suzuki K, Mori N, Kittaka H, Iwata Y, Osonoe K, Niwa SI (1996) Anticonvulsant action of metabotropic glutamate receptor agonists in kindled amygdala of rats. Neurosci Lett 204:41–44PubMedGoogle Scholar
  28. Wada JA (1977) Pharmacological prophylaxis in the kindling model of epilepsy. Arch Neurol 34:387–395Google Scholar
  29. Wada JKA, Osawa T (1976) Spontaneous recurrent seizure state induced by daily amygdaloid stimulation in Senegalese baboons (Papio papio). Neurology 22:273–286Google Scholar
  30. Wada JA, Mizoguichi T, Osawa T (1978) Secondarily generalized convulsive seizures induced by daily amygdaloid stimulation in rhesus monkeys. Neurology 28:1026–1036PubMedGoogle Scholar
  31. Wahnschaffe U, Loescher W (1990) Effect of selective bilateral destruction of the substantia nigra on antiepileptic drug actions in kindled rats. Eur J Pharmacol 186:157–167PubMedGoogle Scholar

Posthypoxic Myoclonus in Rats

  1. Fahn S (1986) Posthypoxic action myoclonus: literature review update. Adv Neurol 43:157–169PubMedGoogle Scholar
  2. Jaw SP, Hussong MJ, Matsumoto RR, Truong DD (1994) Involvement of 5-HT2 receptors in posthypoxic stimulus-sensitive myoclonus in rats. Pharmacol Biochem Behav 49:129–131PubMedGoogle Scholar
  3. Jaw SP, Dang T, Truong DD (1995) Chronic treatments with 5-HT1A agonists attenuate posthypoxic myoclonus in rats. Pharmacol Biochem Behav 52:577–580PubMedGoogle Scholar
  4. Jaw SP, Nguyen B, Vuong QTV, Trinh TA, Nguyen M, Truong DD (1996) Effects of glutamate receptor antagonists in post-hypoxic myoclonus in rats. Brain Res Bull 40:163–166PubMedGoogle Scholar
  5. Lance JW (1968) Myoclonic jerks and falls: aetiology, classification and treatment. Med J Aust 1:113–119PubMedGoogle Scholar
  6. Lance W, Adams RD (1963) The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 86:111–136PubMedGoogle Scholar
  7. Truong DD, Matsumoto RR, Schwartz PH, Hussong MJ, Wasterlain CG (1994) Novel cardiac arrest model of posthypoxic myoclonus. Mov Disord 9:201–206PubMedGoogle Scholar

Rat Kainate Model of Epilepsy

  1. Bardgett ME, Jackson JL, Taylor GT, Csernansky JG (1995) Kainic acid decreases hippocampal neuronal number and increases dopamine receptor binding in the nucleus accumbens: an animal model of schizophrenia. Behav Brain Res 70:153–164PubMedGoogle Scholar
  2. Bolanos AR, Sarkisian M, Yang Y, Hori A, Helmers SL, Mikati M, Tandon P, Stafstrom CE, Holmes GL (1998) Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology 51:41–48PubMedGoogle Scholar
  3. Bouilleret V, Ridoux V, Depaulis A, Marescaux C, Nehling A, LaSalles GLG (1999) Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy. Neuroscience 89:717–729PubMedGoogle Scholar
  4. Cilio MR, Bolanos AR, Liu Z, Schmid R, Yang Y, Stafstrom CE, Mikati MA, Holmes GL (2001) Anticonvulsant action and long-term effects of gabapentin in the immature brain. Neuropharmacology 40:139–147PubMedGoogle Scholar
  5. Csernansky JG, Csernansky CA, Kogelman L, Montgomery EM, Bardgett ME (1998) Progressive neurodegeneration after intracerebroventricular kainic acid administration in rats: implications for schizophrenia? Biol Psychiatry 44:1143–1150PubMedGoogle Scholar
  6. Ebert U, Brandt C, Löscher W (2002) Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia 43(Suppl 5):86–95PubMedGoogle Scholar
  7. Hellier JL, Patrylo PR, Buckmaster PS, Dudek FE (1998) Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy. Epilepsy Res 31:73–84PubMedGoogle Scholar
  8. Hu RQ, Koh S, Torgerson T, Cole AJ (1998) Neuronal stress and injury in C57/BL mice after systemic kainic acid administration. Brain Res 810:229–240Google Scholar
  9. Humphrey WM, Bardgett ME, Montgomery EM, Taylor GT, Csernanansky JG (2001) Methods for inducing neuronal loss in preweanling rats using intracerebroventricular infusion of kainic acid. Brain Res Protocol 7:1–10Google Scholar
  10. Longo BM, Mello LEAM (1998) Supragranular mossy fiber sprouting in rat is not necessary for spontaneous seizures in the intrahippocampal kainate model epilepsy in the rat. Epilepsy Res 32:172–182PubMedGoogle Scholar
  11. Madsen U, Stensbol TB, Krogsgaard-Larsen P (2001) Inhibitors of AMPA and kainate receptors. Curr Med Chem 8:1291–1301PubMedGoogle Scholar
  12. Maj R, Fariello RG, Ukmar G, Varasi M, Pevarello P, McArthur RA, Salvati P (1998) PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol 359:27–32PubMedGoogle Scholar
  13. Pitkânen A, Nissinen J, Jolkkonen E, Tuunanan J, Halonen T (1999) Effects of vigabatrin treatment on status epilepticus-induced neuronal damage and mossy fiber sprouting in the rat hippocampus. Epilepsy Res 33:67–85PubMedGoogle Scholar
  14. Tamagami H, Morimoto K, Watanabe T, Ninomiya T, Hirao T, Tanaka A, Kakumoto M (2004) Quantitative evaluation of central-type benzodiazepine receptors with [125I]Iomazenil in experimental epileptogenesis. I. The rat kainate model of temporal lobe epilepsy. Epilepsy Res 61:105–112PubMedGoogle Scholar

Pilocarpine Model of Epilepsy

  1. André V, Ferrandon A, Marescaux C, Nehlig A (2001) Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 47:99–117PubMedGoogle Scholar
  2. Arida RM, Sanabria ERG, da Silva AC, Faria LC, Scorza FA, Cavalheiro EA (2004) Physical training reverts hippocampal electrophysiological changes in rats submitted to the pilocarpine model of epilepsy. Physiol Behav 83:165–171PubMedGoogle Scholar
  3. Biagini G, Avoli M, Marcinkiewicz J, Marcinkiewicz M (2001) Brain-derived neurotrophic factor superinduction parallels anti-epileptic-neuroprotective treatment in the pilocarpine epilepsy model. J Neurochem 76:1814–1822PubMedGoogle Scholar
  4. Cavalheiro EA, Leite JP, Bortolotto ZA, Turski WA, Ikonomidou C, Turski L (1991) Long-term effects of pilocarpine in rats: structural damages of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia 32:778–782PubMedGoogle Scholar
  5. Honchar MP, Olney JW, Sherman WR (1983) Systemic agents induce seizures and brain damage in lithium-treated rats. Science 220:323–325PubMedGoogle Scholar
  6. Hort J, Brozek G, Mares P, Langmeier M, Komarek V (1999) Cognitive functions after pilocarpine-induced status epilepticus: changes during silent period precede appearance of spontaneous recurrent seizures. Epilpesia 40:1177–1183Google Scholar
  7. Klitgaard H, Matagne A, Vanneste-Goemaere J, Margineanu G (2002) Pilocarpine-induced epileptogenesis in the rat: impact of initial duration of status epilepticus on electrophysiological and neuropathological alterations. Epilepsy Res 51:93–107PubMedGoogle Scholar
  8. Leite JP, Cavalheiro EA (1995) Effect of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 20:93–104PubMedGoogle Scholar
  9. Leite JP, Garcia-Cairasco N, Cavalheiro EA (2002) New insights from the use of pilocarpine and kainate models. Epilepsy Res 50:93–103PubMedGoogle Scholar
  10. Leroy C, Poisbeau P, Keller AF, Nehlig A (2004) Pharmacological plasticity of GABAA receptors at dentate gyrus synapses in a rat model of temporal lobe epilepsy. J Physiol (Lond) 557:473–487Google Scholar
  11. Löscher W (2002) Animal models for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 50:105–123Google Scholar
  12. Lyon A, Marone S, Wainman D, Weaver DF (2004) Implementing a bioassay to screen molecules for antiepileptogenic activity. Chronic pilocarpine versus subdural haematoma models. Seizure 13:82–86PubMedGoogle Scholar
  13. Rigoulot MA, Koning E, Ferrandon A, Nehlig A (2004) Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. J Pharmacol Exp Ther 308:787–795PubMedGoogle Scholar
  14. Setkowicz Z, Ciarach M, Guzik R, Janeczko K (2004) Different effects of neuroprotectants FK-506 and cyclosporine A on susceptibility to pilocarpine-induced seizures in rats with brain injured at different developmental stages. Epilepsy Res 61:63–72PubMedGoogle Scholar
  15. Tang FR, Chia SC, Chen PM, Gao H, Lee WL, Yeo TS, Burgunder JM, Probst A, Sim MK, Ling EA (2004) Metabotropic glutamate receptor 2/3 in the hippocampus of patients with mesial temporal lobe epilepsy, and of rats and mice after pilocarpine-induced status epilepticus. Epilepsy Res 59:167–180PubMedGoogle Scholar
  16. Vergnes M, Marescaux C, Micheletti G, Reis J, Depaulis A, Rumbach L, Warter SM (1982) Spontaneous paroxysmal electroclinical patterns in rat: a model of generalized nonconvulsive epilepsy. Neurosci Lett 33:97–101Google Scholar
  17. Wallace MJ, Blair RE, Falenski KW, Martin BR, Delorenzo RJ (2003) The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307:129–137PubMedGoogle Scholar

Self-Sustained Status Epilepticus

  1. Barton ME, Klein BD, Wolf HH, White HS (2001) Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47:217–227PubMedGoogle Scholar
  2. Brandt C, Glien M, Potschka H, Volk H, Löscher W (2003) Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats. Epilepsy Res 55:83–103PubMedGoogle Scholar
  3. Brown WC, Schiffman DO, Swinyard EA, Goodman LS (1953) Comparative assay of antiepileptic drugs by “psychomotor” seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 107:273–283PubMedGoogle Scholar
  4. De Vasconcelos AP, Mazarati AM, Wasterlain CG, Nehlig A (1999) Self-sustaining status epilepticus after a brief electrical stimulation of the perforant path. A 2-deoxyglucose study. Brain Res 838:110–118Google Scholar
  5. Halonen T, Nissinen J, Jansen JA, Pitkänen A (1996) Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur J Pharmacol 299:69–81PubMedGoogle Scholar
  6. Halonen T, Nissinen J, Pitkänen A (1999) Neuroprotective effect of remacemide hydrochloride in a perforant pathway stimulation model of status epilepticus in the rat. Epilepsy Res 34:251–269PubMedGoogle Scholar
  7. Halonen T, Nissinen J, Pitkänen A (2001) Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment of rats. Epilepsy Res 46:205–223PubMedGoogle Scholar
  8. Laurén HB, Pitkänen A, Nissinen J, Soini SL, Korpi ER, Holopainen IE (2003) Selective changes in gamma-aminobutyric acid type A receptor subunits in the hippocampus in spontaneously seizing rats with chronic temporal lobe epilepsy. Neurosci Lett 349:58–62PubMedGoogle Scholar
  9. Mazarati A, Liu H, Wasterlain C (1999) Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus. Neuroscience 89:167–173PubMedGoogle Scholar
  10. Mazarati AM, Baldwin R, Klitgaard H, Matagne A, Wasterlain CG (2004) Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combination in experimental status epilepticus. Epilepsy Res 58:167–174Google Scholar
  11. Nissinen J, Halonen T, Koivisto E, Pitkänen A (2000) A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat. Epilepsy Res 38:177–205PubMedGoogle Scholar
  12. Pitkänen A, Tuumanen J, Halonen T (1996) Vigabatrin and carbamazepine have different efficacies in the prevention of status epilepticus induced neuronal damage in the hippocampus and amygdala. Epilepsy Res 24:29–45PubMedGoogle Scholar
  13. Walton NY, Jaing Q, Hyun B, Treiman DM (1996) Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res 24:19–28PubMedGoogle Scholar

Rat Model of Cortical Dysplasia

  1. Aicardi J (1994) The place of neuronal migration abnormalities in child neurology. Can J Neurol Sci 21:185–193PubMedGoogle Scholar
  2. Amano S, Ihara N, Umeura S (1996) Development of novel rat mutant with spontaneous limbic-like seizures. Am J Pathol 149:329–336Google Scholar
  3. Baraban SC, Schwartzkroin PA (1995) Electrophysiology of CA1 pyramidal neurons in an animal model of neuronal migration disorders: prenatal methylazoxymethanol treatment. Epilepsy Res 22:145–156PubMedGoogle Scholar
  4. Baraban SC, Schwartzkroin PA (1996) Flurothyl seizure susceptibility in rats following prenatal methylazoxymethanol treatment. Epilepsy Res 23:189–194PubMedGoogle Scholar
  5. Baraban SC, Wenzel HJ, Hochman DW, Schwartzkroin PA (2000) Characterization of heterotopic cell clusters in the hippocampus of rats exposed to methylazoxymethanol in utero. Epilepsy Res 39:87–102PubMedGoogle Scholar
  6. Becker LE (1991) Synaptic dysgenesis. Can J Neurol Sci 18:170–180PubMedGoogle Scholar
  7. Benardete EA, Kriegstein AR (2002) Increased excitability and decreased sensitivity to GABA in an animal model of dysplastic cortex. Epilepsia 43:970–982PubMedGoogle Scholar
  8. Chevassus au Louis N, Baraban SC, Gaiarsa JL, Ben-Ari Y (1999) Cortical malformations and epilepsy: new insight from animal models. Epilepsia 40:811–821PubMedGoogle Scholar
  9. Germano IM, Sperber EF (1997) Increased seizure susceptibility in adult rats with neuronal migration disorders. Brain Res 777:219–222PubMedGoogle Scholar
  10. Hirotsune S, Fleck MW, Gambello MJ, Bix GJ, Chen A, Clark GD, Ledbetter DH, McBain CJ, Wynshaw-Boris A (1998) Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality. Nat Genet 19:333–339PubMedGoogle Scholar
  11. Jacobs KM (1996) Hyperexcitability in a model of cortical maldevelopment. Cereb Cortex 6:514–523PubMedGoogle Scholar
  12. Jacobs KM, Prince DA (2005) Excitatory and inhibitory polysynaptic currents in a rat model of epileptogenic microgyria. J Neurophysiol 93:687–696PubMedGoogle Scholar
  13. Jacobs KM, Hwang BJ, Pronce DA (1999) Focal epileptogenesis in a rat model of polymicrogyria. J Neurophysiol 81:159–173PubMedGoogle Scholar
  14. Lee KS, Schottler F, Collins JL, Lanzino G, Couture D, Rao A, Hiramatsu KI, Goto Y, Hong SC, Caner H, Yamamoto H, Chen ZF, Bertram E, Berr S, Omary R, Scrable H, Jackson T, Goble J, Eisenman L (1997) A genetic animal model of human neocortical heterotypia associated with seizures. J Neurosci 17:6236–6242PubMedGoogle Scholar
  15. Leré C, el Bahh B, La Salle GLG, Rougier A (2002) A model of “epileptic tolerance” for investigating neuroprotection, epileptic susceptibility and gene expression-related plastic changes. Brain Res Protocol 9:49–56Google Scholar
  16. Morimoto K, Watanabe T, Ninomiya T, Hirao T, Tanaka A, Onishi T, Tamagami H (2004) Quantitative evaluation of central-type benzodiazepine receptors with [I125]Iomazenil in an experimental epileptogenesis: II. The rat cortical dysplasia model. Epilepsy Res 61:113–118PubMedGoogle Scholar
  17. Smyth MD, Barbaro NM, Baraban SC (2002) Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia. Epilepsy Res 50:251–264Google Scholar
  18. Wenzel HJ, Robbins CA, Tsai LH, Schwartzkroin PA (2001) Abnormal morphological and functional organization of the hippocampus in a p35 mutant model of cortical dysplasia associated with spontaneous seizures. J Neurosci 21:983–998PubMedGoogle Scholar
  19. Zhu WJ, Roper SN (2000) Reduced inhibition in an animal model of cortical dysplasia. J Neurosci 20:8925–8931PubMedGoogle Scholar

Genetic Animal Models of Epilepsy

  1. Amano S, Ihara N, Uemura S, Yokoyama M, Ikeda M, Serikawa T, Sasahara M, Kataoka H, Hayase Y, Hazama F (1996) Development of a novel rat mutant with spontaneous limbic-like seizures. Am J Pathol 149:329–336Google Scholar
  2. Bartoszewicz ZP, Noronha AB, Fujita N, Sato S, Bo L, Trapp BD, Quarles RK (1995) Abnormal expression and glycosylation of the large and small isoforms of myelinassociated glycoprotein in dysmyelinating quaking mutants. J Neurosci Res 41:27–38PubMedGoogle Scholar
  3. Bartoszyk GD, Hamer M (1987) The genetic animal model of reflex epilepsy in the Mongolian gerbil: differential efficacy of new anticonvulsive drugs and prototype antiepileptics. Pharmacol Res Commun 19:429–440PubMedGoogle Scholar
  4. Batini C, Teillet MA, Naquet R (2004) An avian model of genetic reflex epilepsy. Arch Ital Biol 142:297–312PubMedGoogle Scholar
  5. Bouwman BM, van Rijn CM (2004) Effects of levetiracetam on spike and wave discharges in WAG/Rij rats. Seizure 13:591–594PubMedGoogle Scholar
  6. Budziszewska B, Van Luijtelaar G, Coenen AML, Leźniewicz M, Lasoń W (1999) Effects of neurosteroids on spike-wave discharges in the genetic epileptic WAG/RiJ rat. Epilepsy Res 33:23–29PubMedGoogle Scholar
  7. Chapman AG, Croucher MJ, Meldrum BS (1984) Evaluation of anticonvulsant drugs in DBA/2 mice with sound-induced seizures. Arzneim Forsch/Drug Res 34:1261–1264Google Scholar
  8. Chapman AG, Durmüller N, Harrison BL, Baron BM, Parvez N, Meldrum BS (1995) Anticonvulsant activity of a novel NMDA/glycine site antagonist, MDL 104,653, against kindled and sound-induced seizures. Eur J Pharmacol 274:83–88PubMedGoogle Scholar
  9. Chermat R, Doaré L, Lachapelle F, Simon P (1981) Effects of drugs affecting the noradrenergic system on convulsions in the quaking mouse. Naunyn-Schmiedeberg’s Arch Pharmacol 318:94–99Google Scholar
  10. Coenen AML, Drinkenburg WHIM, Inoue M, Van Luijtelaar ELJM (1992) Genetic models of absence epilepsy, with emphasis on the WAG/RiJ strain of rats. Epilepsy Res 12:75–86PubMedGoogle Scholar
  11. Collins RL (1972) Audiogenic seizures. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy – a manual for the laboratory worker. Raven, New York, pp 347–372Google Scholar
  12. Consroe P, Picchioni A, Chin L (1979) Audiogenic seizure susceptible rats. Fed Proc 38:2411–2416PubMedGoogle Scholar
  13. Crawford RD (1969) A new mutant causing epileptic seizures in domestic fowl. Poult Sci 48:1799Google Scholar
  14. Crawford RD (1970) Epileptic seizures in domestic fowl. J Hered 61:185–188PubMedGoogle Scholar
  15. Cunningham JG (1971) Canine seizure disorders. J Am Vet Med Assoc 158:589–598PubMedGoogle Scholar
  16. Dailey JW, Jobe PC (1985) Anticonvulsant drugs and the genetically epilepsy-prone rat. Fed Proc 44:2640–2644PubMedGoogle Scholar
  17. Dailey JW, Reigel CE, Mishra PK, Jobe PC (1989) Neurobiology of seizure predisposition in the genetically epilepsy-prone rat. Epilepsy Res 3:3–17PubMedGoogle Scholar
  18. Dailey JW, Yan QS, Adams-Curtis LE, Ryu JR, Ko KH, Mishra PK, Jobe PC (1996) Neurochemical correlation of antiepileptic drugs in the genetically epilepsy-prone rat. Life Sci 58:259–266PubMedGoogle Scholar
  19. Danober L, Depaulis A, Vergnes M, Marescaux C (1995) Mesopontine cholinergic control over generalized non-convulsive seizures in a genetic model of absence epilepsy in the rat. Neuroscience 69:1183–1193PubMedGoogle Scholar
  20. Danober L, Deransart C, Depaulis A, Vergnes M, Marescaux C (1998) Pathophysiological mechanisms of genetic absence epilepsy in the rat. Prog Neurobiol 55:27–57PubMedGoogle Scholar
  21. Deransart C, Riban V, Lê BT, Marescaux C, Depaulis A (2000) Dopamine in the striatum modulates seizures in a genetic model of absence epilepsy in the rat. Neuroscience 100:335–344PubMedGoogle Scholar
  22. Di Pasquale E, Keegan KD, Noebels JL (1997) Increase excitability and inward rectification in layer V cortical pyramidal neurons in the epileptic mouse stargazer. J Neurophysiol 77:621–631PubMedGoogle Scholar
  23. Edmonds HL, Hegreberg GA, van Gelder NM, Sylvester DM, Clemmons RM, Chatburn CG (1979) Spontaneous convulsions in beagle dogs. Fed Proc 38:2424–2428PubMedGoogle Scholar
  24. Faingold CL (1988) The genetically epilepsy-prone rat. Gen Pharmacol 19:331–338PubMedGoogle Scholar
  25. Faingold CL, Naritoku DK (1992) The genetically epilepsy-prone rat: neuronal networks and actions of amino acid neurotransmitters. In: Faingold CL, Fromm GH (eds) Drugs for control of epilepsy: actions on neuronal networks involved in seizure disorders. CRC Press, Boca Raton, pp 277–308Google Scholar
  26. Faingold CL, Randall ME, Boersma Anderson CA (1994) Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat. Exp Neurol 126:225–232PubMedGoogle Scholar
  27. Famula TR, Oberbauer AM, Brown KN (1997) Heritability of epileptic seizures in the Belgian tervueren. J Small Anim Pract 38:349–352PubMedGoogle Scholar
  28. Fletcher CF, Lutz CM, O’Sullivan TM, Shaughnessy JD Jr, Hawkes R, Frankel WN, Copeland NG, Jenkins NA (1996) Absence epilepsy in tottering mutant mice is associated with calcium channel deficits. Cell 87:607–617PubMedGoogle Scholar
  29. Galvis-Alonzo OY, Cortes de Oliveira JA, Garcia-Cairasco N (2004) Limbic epileptogenicity, cell loss and axonal reorganization induced by audiogenic and amygdala kindling in Wistar audiogenic rats (WAR strain). Neuroscience 125:787–802Google Scholar
  30. Green RC, Seyfried TN (1991) Kindling susceptibility and genetic seizure predisposition in inbred mice. Epilepsia 32:22–26PubMedGoogle Scholar
  31. Green MC, Sidman RL (1962) Tottering – a neuromuscular mutation in the mouse. J Hered 53:233–237PubMedGoogle Scholar
  32. Heckroth JA, Abbott LC (1994) Purkinje cell loss from alternating sagittal zones in the cerebellum of leaner mutant mice. Brain Res 658:93–104PubMedGoogle Scholar
  33. Herrup K, Wilczynsnki SL (1982) Cerebellar cell degeneration in the leaner mutant mouse. Neuroscience 7:2185–2196PubMedGoogle Scholar
  34. Hogan EL (1977) Animals models of genetic disorders of myelin. In: Morell P (ed) Myelin. Plenum Press, New York, pp 489–520Google Scholar
  35. Hosford DA, Lin FH, Wang Y, Caddick SJ, Rees M, Parkinson NJ, Barclay J, Cox RD, Gardiner RM, Hosford DA, Denton P, Wang Y, Seldin MF, Chan B (1999) Studies of the lethargic (Ih/lh) mouse model of absence seizures: regulatory mechanisms and identification of the gene. Adv Neurol 79:239–252PubMedGoogle Scholar
  36. Iida K, Sasa M, Serikawa T, Noda A, Ishihara K, Akimitsu T, Hanaya R, Arita K, Kurisu K (1998) Induction of convulsive seizures by acoustic priming in a new genetically defined model of epilepsy (Noda epileptic rat: NER). Epilepsy Res 30:115–126PubMedGoogle Scholar
  37. Imaizumi K, Ito S, Kutukake G, Takizawa T, Fujiwara K, Tutikawa K (1959) Epilepsy like anomaly of mice. Exp Anim (Tokyo) 8:6–10Google Scholar
  38. Jobe PC, Mishira PK, Dailey JW (1992) Genetically epilepsy-prone rats: actions of antiepileptic drugs and monoaminergic neurotransmitters. In: Faingold CL, Fromm GH (eds) Drugs for control of epilepsy: actions on neuronal networks involved in seizure disorders. CRC Press, Boca Raton, pp 253–275Google Scholar
  39. Jobe PC, Mishra PK, Adams-Curtis LE, Deoskar VU, Ko KH, Browning RA, Dailey JW (1995) The genetically epilepsy-prone rat (GEPR). Ital J Neurol Sci 16:91–99PubMedGoogle Scholar
  40. Johnson DD, Davis HL, Crawford RD (1979) Pharmacological and biochemical studies in epileptic fowl. Fed Proc 38:2417–2423PubMedGoogle Scholar
  41. Killam EK, Killam KF Jr (1984) Evidence for neurotransmitter abnormalities related to seizure activity in the epileptic baboon. Fed Proc 43:2510–2515PubMedGoogle Scholar
  42. Killam KF, Naquet R, Bert J (1966) Paroxysmal responses to intermittent light stimulation in a population of baboons (Papio papio). Epilepsia 7:215–219Google Scholar
  43. Killam KF, Killam EK, Naquet R (1967) An animal model of light sensitivity epilepsy. Electroencephalogr Clin Neurophysiol 22:497–513PubMedGoogle Scholar
  44. King JT Jr, LaMotte CC (1989) El mouse as a model of focal epilepsy. Epilepsia 30:257–265PubMedGoogle Scholar
  45. Ko KH, Dailey JW, Jobe PC (1982) Effect of increments of norepinephrine concentrations on seizure intensity in the genetically epilepsy-prone rat. J Pharmacol Exp Ther 222:662–669PubMedGoogle Scholar
  46. Kuebler D, Tanouye MA (2000) Modification of seizure susceptibility in Drosophila. J Neurophysiol 83:998–1009PubMedGoogle Scholar
  47. Kuebler D, Zhang H, Ren X, Tanouye MA (2001) Genetic suppression of seizure susceptibility in Drosophila. J Neurophysiol 86:1211–1225PubMedGoogle Scholar
  48. Kurtz BS, Lehman J, Galick P, Amberg J, Mishra PK, Daikey JW, Weber R, Jobe PC (2001) Penetrance and expressivity of genes involved in the development of epilepsy in the genetically epilepsy-prone rat (GEPR). J Neurogenet 15:233–244PubMedGoogle Scholar
  49. Laird HE 2nd (1989) The genetically epilepsy-prone rat. A valuable model for the study of epilepsies. Mol Chem Neuropathol 11:45–59PubMedGoogle Scholar
  50. Lakaye B, Thomas E, Minet A, Grisar T (2002) The genetic absence epilepsy rat from Strasbourg (GAERS), a rat model of epilepsy: computer modeling and differential gene expression. Epilepsia 43(Suppl 5):123–129PubMedGoogle Scholar
  51. Lee RJ, Lomax P (1984) The effect of spontaneous seizures on pentylenetetrazole and maximum electroshock induced seizures in the Mongolian gerbil. Eur J Pharmacol 106:91–98PubMedGoogle Scholar
  52. Lee RJ, Hong JS, McGinty JF, Lomax P (1987) Increased enkephalin and dynorphin immunoreactivity in the hippocampus of seizure sensitive Mongolian gerbils. Brain Res 401:353–358PubMedGoogle Scholar
  53. Letts VA, Mahaffey CL, Beyer B, Frankel WN (2005) A targeted mutation in Cacng4 exacerbates spike-wave seizures in stargazer (Cacng2) mice. Proc Natl Acad Sci U S A 102:2123–2128PubMedCentralPubMedGoogle Scholar
  54. Li W-X, Kuchler S, Zaepfel M, Badache A, Thomas D, Vincedon G, Baumann N, Zanetta JP (1993) Cerebellar soluble lectin and its glycoprotein ligands in the developing brain of control and dysmyelinating mutant mice. Neurochem Int 22:125–133PubMedGoogle Scholar
  55. Löscher W (1984) Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review. Methods Find Exp Clin Pharmacol 6:531–547PubMedGoogle Scholar
  56. Löscher W, Frey HH (1984) Evaluation of anticonvulsant drugs in gerbils with reflex epilepsy. Arzneim Forsch/Drug Res 34:1484–1488Google Scholar
  57. Löscher W, Meldrum BS (1984) Evaluation of anticonvulsant drugs in genetic animal models of epilepsy. Fed Proc 43:276–284PubMedGoogle Scholar
  58. Löscher W, Fisher JE Jr, Schmidt D, Fredow G, Honack D, Iturrian WB (1989) The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Mov Disord 4:219–232PubMedGoogle Scholar
  59. Loskota WJ, Lomax P, Rich ST (1974) The gerbil as a model for the study of epilepsies. Epilepsia 15:109–119PubMedGoogle Scholar
  60. Magalhães LHM, Garcia-Cairasco N, Massensini AR, Doretto MC, Moraes MFD (2004) Evidence for augmented brainstem activated forebrain seizures in Wistar Audiogenic rats subjected to transauricular electroshock. Neurosci Lett 369:19–23PubMedGoogle Scholar
  61. Majkowski J, Kaplan H (1983) Value of Mongolian gerbils in antiepileptic drug evaluation. Epilepsia 24:609–615PubMedGoogle Scholar
  62. Mitrovic N, Le Saux R, Gioanni H, Gioanni Y, Besson MJ, Maurin Y (1992) Distribution of [3H]clonidine binding sites in the brain of the convulsive mutant quaking mouse: a radioautographic analysis. Brain Res 578:26–32PubMedGoogle Scholar
  63. Moraes MFD, Chavali M, Mishra PK, Jobe PC, Garcia-Cairasco N (2005) A comprehensive electrographic and behavioral analysis of generalized tonic-clonic seizures of GEPR-9s. Brain Res 1033:1–12PubMedGoogle Scholar
  64. Naquet R, Meldrum BS (1972) Photogenic seizures in baboon. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy – a manual for the laboratory worker. Raven, New York, pp 373–406Google Scholar
  65. Nehling A, Boehrer A (2003) Effects of remacemide in two models of genetically determined epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsy Res 52:253–261Google Scholar
  66. Nikulina EM, Skrinskaya JA, Avgustinovich DF, Popova NK (1995) Dopaminergic brain system in the quaking mutant mouse. Pharmacol Biochem Behav 50:333–337PubMedGoogle Scholar
  67. Noda A, Hashizume R, Maihara T, Tomizawa Y, Ito Y, Inoue M, Kobayashi K, Asano Y, Sasa M, Serikawa T (1998) NER rat strain: a new type of genetic model in epilepsy research. Epilepsia 39:99–107PubMedGoogle Scholar
  68. Noebels JL (1979) Analysis of inherited epilepsy using single locus mutations in mice. Fed Proc 38:2405–2410PubMedGoogle Scholar
  69. Noebels JL, Sidman RL (1979) Inherited epilepsy: spike-wave and focal motor seizures in the mutant mouse tottering. Science 204:1334–1336PubMedGoogle Scholar
  70. Noeberls JL, Qiao X, Bronson RT, Spencer C, Davisson MT (1990) Stargazer, a new neurological mutant in chromosome 15 in the mouse with prolonged cortical seizures. Epilepsy Res 7:129–135Google Scholar
  71. Oberbauer AM, Grossmann DI, Irion DN, Schaffer AL, Eggleston ML, Famula TR (2003) The genetics of epilepsy in the Belgian tervuren and sheepdog. J Hered 94:57–63PubMedGoogle Scholar
  72. Oguro K, Ito M, Tsuda H, Mutoh K, Shiraishi H, Shirasaka Y, Mikawa H (1991) Association of NMDA receptor sites and seizures E1 mice. Epilepsy Res 9:225–230PubMedGoogle Scholar
  73. Patel S, Chapman AG, Graham JL, Meldrum BS, Frey P (1990) Anticonvulsant activity of NMDA antagonists, D(−)4-(3-phosphonopropyl)piperazine-2-carboxylic acid (D-CPP) and D(−)(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (D-CPPene) in a rodent and a primate model of reflex epilepsy. Epilepsy Res 7:3–10PubMedGoogle Scholar
  74. Quesney LF (1984) Pathophysiology of generalized photosensitive epilepsy in the cat. Epilepsia 25:61–69PubMedGoogle Scholar
  75. Racine RJ, Steingart M, McIntyre DC (1999) Development of kindling-prone and kindling resistant rats: selective breeding and electrophysiological studies. Epilepsy Res 35:183–195PubMedGoogle Scholar
  76. Reigel CE, Dailey JW, Jobe PC (1986) The genetically epilepsy-prone rat: an overview of seizure-prone characteristics and responsiveness to anticonvulsant drugs. Life Sci 39:763–774PubMedGoogle Scholar
  77. Sarkisian MR, Rattan S, D’Mello SR, LoTurco LL (1999) Characterization of seizures in the flathead rat: a new genetic model in early postnatal development. Epilepsia 40:394–400PubMedGoogle Scholar
  78. Sarkisova KY, Midzianovskaia IS, Kulikov MA (2003) Depressive-like behavioral alterations and c-fos expression in the dopaminergic brain regions in WAG/Rij rats with genetic absence epilepsy. Behav Brain Res 144:211–226PubMedGoogle Scholar
  79. Sasa M, Ohno Y, Ujihara H, Fujita Y, Yoshimura M, Takaori S, Serikawa T, Yamada J (1988) Effects of antiepileptic drugs on absence-like and tonic seizures in the spontaneously epileptic rat, a double mutant rat. Epilepsia 29:505–513PubMedGoogle Scholar
  80. Scarlatelli-Lima AV, Magalhães LHM, Doretto MC, Moraes MFD (2003) Assessment of the seizure susceptibility of Wistar Audiogenic rat to electroshock, pentylenetetrazole and pilocarpine. Brain Res 960:184–189PubMedGoogle Scholar
  81. Seki T, Matsubayashi H, Amano T, Kitada K, Serikawa T, Sakai N, Sasa M (2002) Adenoviral gene transfer of aspartoacyclase into the tremor rat, a genetic model of epilepsy, as a trial of gen therapy for inherited epileptic disorder. Neurosci Lett 328:249–252PubMedGoogle Scholar
  82. Serikawa T, Yamada J (1986) Epileptic seizures in rats homozygous for two mutations, zitter and tremor. J Hered 77:441–444PubMedGoogle Scholar
  83. Serikawa T, Ohno Y, Sasa M, Yamada J, Takori S (1987) A new model of petit mal epilepsy: spontaneous spike and wave discharges in tremor rats. Lab Anim 21:68–71PubMedGoogle Scholar
  84. Serikawa T, Kogishi K, Yamada J, Ohno Y, Ujihara H, Fujita Y, Sasa M, Takaori S (1990) Long-term effects of continual intake of phenobarbital on the spontaneously epileptic rat. Epilepsia 31:9–14PubMedGoogle Scholar
  85. Seyfried TN (1979) Audiogenic seizures in mice. Fed Proc 38:2399–2404PubMedGoogle Scholar
  86. Seyfried TN, Glaser GH, Yu RK, Palayoor ST (1986) Inherited convulsive disorders in mice. Adv Neurol 44:115–133PubMedGoogle Scholar
  87. Sidman M, Ray BA, Sidman RL, Klinger JM (1966) Hearing and vision in neurological mutant mice: a method for their evaluation. Exp Neurol 16:377–402PubMedGoogle Scholar
  88. Smith SE, Dürmüller N, Meldrum BS (1991) The non-N-methyl-d-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 201:179–183PubMedGoogle Scholar
  89. Srenk P, Jaggy A, Gaillard C, Busato A, Horlin P (1994) Genetische Grundlagen der idiopathischen Epilepsie beim Golden Retriever. Tierärztl Prax 22:574–578PubMedGoogle Scholar
  90. Stark LG, Killam KF, Killam EK (1970) The anticonvulsant effects of phenobarbital, diphenylhydantoin and two benzodiazepines in the baboon, Papio papio. J Pharmacol Exp Ther 173:125–132PubMedGoogle Scholar
  91. Stenger A, Boudou JL, Briley M (1991) Anticonvulsant effect of some anxiolytic drugs on two models of sound-induced seizures in mice. In: Briley M, File SE (eds) New concepts in anxiety. McMillan Press, London, pp 326–331Google Scholar
  92. Suzuki J (2004) Investigations of epilepsy with a mutant animal (EL mouse) model. Epilepsia 45(Suppl 8):2–5PubMedGoogle Scholar
  93. Tacke U, Björk E, Tuomisto J (1984) The effect of changes in sound pressure level and frequency on the seizure response of audiogenic seizure susceptible rats. J Pharmacol Methods 11:279–290PubMedGoogle Scholar
  94. Tehrani MH, Baumgartner BJ, Liu SC, Barnes EM Jr (1997) Aberrant expression of GABAA receptor subunits in the tottering mouse: an animal model for absence seizures. Epilepsy Res 28:213–223PubMedGoogle Scholar
  95. Thiessen DD, Lindzey G, Friend HC (1968) Spontaneous seizures in the Mongolian gerbil (Meriones unguiculatus). Psychol Sci 11:227–228Google Scholar
  96. Tsubota Y, Miyashita E, Miyajima M, Owada-Makabe K, Yukawa K, Maeda M (2003) The Wakayama epileptic rat (WER), a new mutant exhibiting tonic-clonic seizures and absence-like seizures. Exp Anim 52:53–62PubMedGoogle Scholar
  97. Ujihara H, Renming X, Sasa M, Ishihara K, Fujita Y, Yoshimura M, Kishimoto T, Serikawa T, Yamada J, Takaori S (1991) Inhibition by thyrotropin-releasing hormone of epileptic seizures in spontaneously epileptic rats. Eur J Pharmacol 196:15–19PubMedGoogle Scholar
  98. Van Luijtelaar ELJM, Coenen AML (1986) Two types of electrocortical paroxysms in an inbred strain of rats. Neurosci Lett 70:393–397PubMedGoogle Scholar
  99. Van Luijtelaar ELJM, Budziszewska B, Tetich M, Lasoń W (2003) Finasteride inhibits the progesterone-induced spike-wave discharges in a genetic model of absence epilepsy. Pharmacol Biochem Behav 75:889–894PubMedGoogle Scholar
  100. Vergnes M, Marescaux C, Micheletti G, Reis J, Depaulis A, Rumbach L, Warter SM (1982) Spontaneous paroxysmal electroclinical patterns in the rat: A model of generalized non-convulsive epilepsy. Neurosci Lett 33:97–101Google Scholar
  101. Wang H, Burdette LJ, Frankel WN, Masukawa LM (1997) Paroxysmal discharges in the EL mouse, a genetic model of epilepsy. Brain Res 760:266–271PubMedGoogle Scholar
  102. Xie R, Fujita Y, Sasa M, Ishihara K, Ujihara H, Takaori S, Serikawa T, Jamada J (1990) Antiepileptic effect of CNK-602A, a TRH analogue, in the spontaneously epileptic rat (SER), a double mutant. Jpn J Pharmacol 52(Suppl 1):290PGoogle Scholar
  103. Zhang HG, Tan J, Reynolds E, Kuebler D, Faulhaber S, Tanouye M (2002) The Drosophila slamdance gene: a mutation in an aminopeptidase can cause seizures, paralysis and neuronal failure. Genetics 162:1283–1299PubMedCentralPubMedGoogle Scholar

Transgenic Animals as Models of Epilepsy

  1. Allen KM, Walsh CA (1999) Genes that regulate neuronal migration in the cerebral cortex. Epilepsy Res 36:143–154PubMedGoogle Scholar
  2. Butler LS, Silva AJ, Abeliovich A, Watanabe Y, Tonegawa S, McNamara JO (1995) Limbic epilepsy in transgenic mice carrying a Cα 2+/calmodulin-dependent kinase II α-subunit mutation. Proc Natl Acad Sci U S A 92:6852–6855PubMedCentralPubMedGoogle Scholar
  3. Campbell KM, Veldman MB, McGrath MJ, Burton FH (2000) TS + OCD-like neuropotentiated mice are supersensitive to seizure induction. Neuroreport 11:2335–2338PubMedGoogle Scholar
  4. Diano S, Matthews RT, Patrylo P, Yang L, Beal MF, Barnstable CJ, Horvath TL (2005) Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology 144:5014–5021Google Scholar
  5. Ferri AL, Cavallaro M, Braida D, Di-Christofano A, Canta A, Vezzani A, Ottolenghi S, Pandolfi PP, Sala M, DeBiasi S, Nicolis SK (2004) Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development 131:3805–3819PubMedGoogle Scholar
  6. Giorgi FS, Pizzanelli C, Biagioni F, Murri L, Fornai F (2004) The role of epinephrine ion epilepsy: from the bench to the bedside. Neurosci Behav Rev 28:507–524Google Scholar
  7. Kearney JA, Plummer NW, Smith MR, Kapur J, Cummins TR, Waxman SG, Goldin AR, Meisler MH (2001) A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities. Neuroscience 102:307–317PubMedGoogle Scholar
  8. Knuesel I, Riban V, Zuellig RA, Schaub MC, Grady RM, Sanes JR, Fritschy JM (2002) Increase vulnerability to kainate-induced seizures in utrophin-knockout mice. Eur J Neurosci 15:1474–1484PubMedGoogle Scholar
  9. Kokaia M, Holmberg K, Nanobashvili A, Xu ZQD, Kokaia Z, Lendahl U, Hilke S, Theodorsson E, Kahl U, Bartfai T, Lindvall O, Hökfelt T (2001) Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci U S A 98:14006–14011PubMedCentralPubMedGoogle Scholar
  10. Kunieda T, Zuscik MJ, Boongird A, Perez DM, Luders HO, Najim IM (2002) Systemic overexpression of the alpha 1Badrenergic receptor in mice: an animal model of epilepsy. Epilepsia 43:1324–1329PubMedGoogle Scholar
  11. Lahteinen S, Pitkanen A, Saarelainen T, Nissinen J, Koponen E, Castren E (2002) Decreased BDNF signaling in transgenic mice reduces epileptogenesis. Eur J Neurosci 15:721–734PubMedGoogle Scholar
  12. Lahteinen S, Pitkanen A, Koponen E, Saarelainen T, Castren E (2003) Exacerbated status epilepticus and acute cell loss, but no changes in epileptogenesis, in mice with increased brain-derived neurotrophic factor signaling. Neuroscience 122:1081–1092PubMedGoogle Scholar
  13. Lahteinen S, Pitkanen A, Knuuttila J, Toronen P, Castren E (2004) Brain-derived neurotrophic factor signaling modifies hippocampal gene expression during epileptogenesis in transgenic mice. Eur J Neurosci 19:3245–3254PubMedGoogle Scholar
  14. Liang LP, Ho YS, Patel M (2000) Mitochondrial superoxide production in kainate-induced hippocampal damage. Neuroscience 101:563–570PubMedGoogle Scholar
  15. Ludwig A, Budde T, Stieber J, Moosmang S, Langebartels A, Wotjak C, Munsch T, Zong X, Feil S, Feil R, Lancel M, Chien KR, Konnerth A, Pape HC, Biel M, Hofmann F (2003) Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. EMBO J 22:216–224PubMedCentralPubMedGoogle Scholar
  16. Lüthi A, van der Putten H, Botteri FM, Mansuy IM, Meins M, Frey U, Sansig G, Portet C, Schmutz M, Schröder M, Nitsch C, Laurent JP, Monard D (1997) Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J Neurosci 17:34688–34699Google Scholar
  17. Mazarati A, Lu X, Shinmei S, Badie-Mahdavi H, Bartfai T (2004) Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GALR1) knockout mice. Neuroscience 128:431–441Google Scholar
  18. Meldrum BS, Akbar MT, Chapman AG (1999) Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res 36:189–204PubMedGoogle Scholar
  19. Musumeci SA, Bosco B, Calabrese G, Bakker C, De-Sarro GB, Elia M, Ferri R, Oostra BA (2000) Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41:19–23PubMedGoogle Scholar
  20. Noebels JL (1999) Single-gene models of epilepsy. Adv Neurol 79:227–238PubMedGoogle Scholar
  21. Peters HC, Hu H, Pongs O, Storm JF, Isbrandt D (2005) Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior. Nat Neurosci 8:51–60PubMedGoogle Scholar
  22. Potschka H, Krupp E, Ebert U, Gumbel C, Leichtlein C, Lorch B, Pickert A, Kramps S, Young K, Grune U, Keller A, Welschof M, Vogt G, Xiao B, Worley PF, Löscher W, Hiemisch H (2002) Kindling-induced overexpression of Homer 1A and its functional implications for epileptogenesis. Eur J Neurosci 16:2157–2165PubMedGoogle Scholar
  23. Prasad AN, Prasad C, Stafstrom CE (1999) Recent advances in the genetics of epilepsy: insights from human and animal studies. Epilepsia 40:1329–1352PubMedGoogle Scholar
  24. Schauwecker PE (2002) Complications associated with genetic background effects in models of experimental epilepsy. Prog Brain Res 135:139–148PubMedGoogle Scholar
  25. Shannon H, Yang L (2004) Seizure susceptibility of neuropeptide-Y null mutant mice in amygdala kindling and chemical-induced seizure models. Epilepsy Res 61:49–62PubMedGoogle Scholar
  26. Shimizu T, Ikegami T, Ogawara M, Suzuki Y, Takahashi M, Morio H, Shirasawa T (2002) Transgenic expression of the protein-l-isoaspartyl methyltransferase (PIMT) gene in the brain rescues mice from the fatal epilepsy of PIMT deficiency. J Neurosci Res 69:341–352PubMedGoogle Scholar
  27. Toth M, Tecott L (1999) Transgenic approaches to epilepsy. Adv Neurol 79:291–296PubMedGoogle Scholar
  28. Upton N, Stratton S (2003) Recent developments from genetic mouse models of epilepsy. Curr Opin Pharmacol 3:19–26PubMedGoogle Scholar
  29. Viswanath V, Wu Z, Fonck C, Wei Q, Boonplueang R, Andersen JK (2000) Transgenic mice neuronally expressing baculoviral p35 are resistant to diverse types of induced apoptosis, including seizure-associated neurodegeneration. Proc Natl Acad Sci U S A 97:2270–2275PubMedCentralPubMedGoogle Scholar
  30. Weinshenker D, Szot P (2002) The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol Ther 94:213–233PubMedGoogle Scholar
  31. Yang Y, Frankel WN (2004) Genetic approaches to studying mouse model of human seizure disorders. Adv Exp Med Biol 548:1–11PubMedGoogle Scholar
  32. Zeng Z, Kyaw H, Gakenheimer KR, Augustus M, Fan P, Zhang X, Su K, Carter KC, Li Y (1997) Cloning, mapping, and tissue distribution of a human homologue of the mouse jerky gene product. Biochem Biophys Res Commun 236:389–395PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Kallman Preclinical ConsultingGreenfieldUSA

Personalised recommendations